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Chapter I 
General Introduction 

Introduction 
Treatment of chronic hepatitis B: Immune modulation in chronic hepatitis B patients. 
Hepatitis B virus morphology and replication 
The hepatitis B virus (HBV) is a 42 nm viral particle and member of the hepadnaviridae family. 
Its double-shelled structure consists of an outer envelop composed of surface proteins 
(HBsAg) and an inner capsid formed by core-proteins (HBcAg) surrounding the partially double 
stranded DNA (1). The HBV DNA has 4, partially overlapping, open reading frames (ORF's) 
encoding for the viral antigens. 
ORF P is the longest one and has four contiguous regions: one encoding for the terminal 
protein (a covalently bound protein necessary for minus strand syntheses priming (primase)), a 
second non-specific domain (spacer), a third for the reverse transcriptase and a fourth domain 
encoding for RNaseH. 
ORF S encodes for the pre-S1, pre-S2 proteins and the HBs-antigen and is completely located 
within ORF P. In particular pre-S1 is suggested to be important for viral attachment (2). HBsAg 
contains the major antigenic a-determinant. HBsAg is produced at the membrane of the 
endoplasmic reticulum (ER): complete virions, the non-infectious filaments (containing small, 
middle and large HBsAg proteins) or spheres (consisting of small and middle-sized HBsAg 
proteins) circulate in serum in excess. 
ORF C encodes for the (pre-) core proteins, HBeAg and HBcAg. The core particles are 
postulated to be necessary for the assembly of the virus. HBcAg is synthesized in the cytosol 
and can be stored in the nucleus. In serum however, it is undetectable in contrast to the 
secretory form of the core protein, HBeAg. 
ORF X expresses the X-gene, the putative transcriptional activator of several genes. Both ORF 
C and ORF X partially overlap with ORF P (1). 
After attachment of HBV to the host cell membrane, the viral DNA is uncoated and translocated 
to the cell nucleus where it is repaired and fully double-stranded covalently closed circular DNA 
(ccc-DNA) is formed. The ccc-DNA acts as a template tor the transcription of mRNA's among 
which the RNA pre-genome regulated by host RNA polymerase. These transcripts are 
transported to the cy1oplasm. The core particles aggregate and encapsidize at least one HBV 
polymerase protein and the pre-genomic RNA to form the core particle. In this replicating 
complex a minus DNA strand will be formed after priming of the reverse transcriptase by HBV 
polymerase. RNaseH degrades the pre-genomic RNA, with the exception of a small region at 
the 5' end, which is the primer of the plus-strand formation. The small, middle and large HBsAg 
transcripts are transported to the ER and can envelop core particles after budding into the 
lumen of the ER, followed by release of the virion in serum by exocy1osis (1, 3). 
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Chronic Hepatitis B virus infection 
Chronic HBV infection is defined as persistence of HBV replication for more than 6 months 
after the acute infection. Worldwide, approximately 350 million people are chronic HBV 
carriers. Chronic HBV can progress to liver failure, portal hypertension and hepatocellular 
carcinoma (4). Complications of HBV infection are accountable for the death of around one 
million people each year. 
Active viral replication is reflected by detectable serum HBV DNA and HBeAg levels, except 
in patients infected with a pre-core mutant in whom HBeAg is undetectable. Viral replication 
is often accompanied by fluctuating serum transaminase values. HBeAg seroconversion is 
usually followed by normalization of serum transaminases and improvement of liver histology 
(5-8). In patients with cirrhosis clinical outcome and survival in chronic HBV is significantly 
improved after HBeAg seroconversion, especially biochemical disease remission seems to 
be an important factor (5, 9-10). Therefore achieving sustained HBeAg seroconversion is the 
major goal of antiviral therapy in HBV. 
Antiviral therapy in chronic hepatitis B virus infection 
Two drugs are registered for the treatment of CHB: interferon-alpha (IFN), since the early 
nineties, and lamivudine (Zeffix"), since the end of 1999. Several new immune modulating 
drugs and nucleoside analogues are under investigation. 
I. Immune modulating drugs 
1.Aipha-lnterferon 
IFN-a has direct and indirect antiviral properties, which are of major importance in the host 
defense system against viral infections (11). After binding to its cell membrane receptor, IFN-a 
stimulates the transcription of a wide variety of proteins. Some have antiviral or 
immunomodulatory effects, however the function of most proteins is unknown. IFN-a acts as 
an immunostimulator by enhancing the expression of HLA class I antigens, which will probably 
facilitate the NK cell and cytotoxic T-cell mediated killing of infected hepatocytes (11-12). In 
addition IFN acts by blocking of entry and uncoating of the virus and inhibiting of the production 
of pre-genomic m-RNA (11-13). 
Loss of HBeAg following IFN therapy is reported in 20 to 40% of patients, this response is 
sustained in 80 to 90% of responders (5, 7, 9, 14-15). Prolongation of IFN therapy to 32 weeks 
may enhance the efficacy and in those patients who failed to a standard course re-treatment 
given in an adequate dose may be beneficial (16-17). In general the HBeAg seroconversion 
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rate strongly depends on baseline AL T levels and IFN increases the spontaneous response 
rate by a factor 1.8 (18). IFN responders are more likely to completely clear HBV DNA (by 
PCR) and HBsAg compared to spontaneous HBeAg-seroconverters (5, 7, 9). Depending on 
the duration of follow up (4 to 9 years), eventually 15-55% of patients loose HBV DNA (PCR) 
from serum and 23-86% become HBsAg negative (6-7, 9,19-20). Patients clearing HBeAg 
following IFN therapy have a significantly lower risk to develop cirrhosis and an improved 
survival rate (5, 10, 21-22). 
Pegylated interferon-alpha (IFN covalently binded to a polyethylene glycol molecule) has been 
developed increasing the half-life of IFN significantly. This allows dosing once weekly instead 
of three times weekly. Efficacy may be enhanced, side effects may be reduced. Pegylated IFN 
is currently evaluated in chronic HBV and HCV. The limited efficacy and the numerous serious 
side effects of standard IFN have initiated the search for other therapeutical approaches such 
as new immune modulating drugs and nucleoside analogues. 
2. Other immunostimulatory drugs 
a. The use of Therapeutic vaccination in chronic HBV patients to induce an immune response 
has been a subject of investigation for years. Although pilot studies show encouraging results, 
no clear benefit has been shown yet. Roughly three groups of specific vaccines have been 
investigated so far: the recombinant HBV vaccines, T -cell vaccines and genetic DNA vaccines. 
Several pilot studies on HBs-vaccines showed encouraging results (23-26). One study showed 
a CD4• mediated (Th1) response in part of the patients (7127) after vaccination with HBsAg 
(23). In another pilot study using a vaccine consisting of the HBV envelope antigen together 
with a new adjuvant system sustained loss of HBeAg was obtained in 15% of patients (24). 
However in this study no placebo group was included. One large controlled trial has been 
published so far, including 118 patients treated with a PreS2/S vaccine (GeHevac B), an S 
vaccine (Recombivax) or placebo. Vaccination with either vaccine was followed by a significant 
decrease in HBV DNA Although an increased HBeAg seroconversion rate was observed 
compared to placebo (13.3% versus 3.6% respectively) this did not reach statistical 
significance (25). 
The Hepatitis B core antigen based vaccine Theradigm-HBVrM, is a single-epitope vaccine 
consisting of a cytotoxic T cell (CTL) epitope derived from the HBV core protein incorporated 
into a vaccine comprising a T-helper cell epitope and two palmic acid molecules. It has been 
used to induce a CTL response to HBV. Although the vaccine was able to induce a CTL-
response, the magnitude of this response was below the level observed following a resolved 
acute HBV infection (27-28). 
DNA-based vaccines (consisting of plasmid DNA encoding HBV envelop proteins) have been 
only evaluated in mouse models so far. 
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b. Thymosine alpha 1 (Talpha1) is an immunomodulatory peptide. In Asians a significant 
increased HBeAg loss at the end of follow-up was shown in patients following Talpha1 therapy 
compared to placebo. However these favorable results could not be confirmed in another large 
multi-center trial in chronic HBeAg positive HBV patients (29-30). 
c. Cytokine therapy. The efficacy of IL12 has been investigated in a phase 1111 trial including 
116 chronic HBV patients who received 0.03 11g, 0.25 11g or 0.50 11g rHuiL 12 once weekly for 
12 weeks. Follow-up was 12 weeks. Although a significant decrease in HBV DNA was 
observed at the end of therapy, sustained HBeAg seroconversion was limited to the 2 groups 
receiving 0.25 11g and 0.50 11g rHuiL 12. At the end of follow-up 16% (5131) showed loss of 
HBeAg and gain ofanti-HBe (31). 
Cytokine therapy with IFN-~ -ory or TN F-a is under investigation. 
d. Anti-HBs is used after liver transplantation in HBV patients to prevent re-infection of the 
graft, in newborns of HBV infected women to prevent perinatal transmission and as post-
exposure prophylaxis. In the treatment of chronic HBV the use of anti-HBs as an immune 
modulator has only been studied in 2 small studies. Passive immunization with anti-HBs in 6 
chronic HBsAg positive patients induced a (temporary) decrease or clearance of serum HBsAg 
(32). Monoclonal anti-HBs given in chronic HBV patients with active disease caused a 
(temporary) drop in HBV DNA and HBsAg levels (33). In addition in 2 patients with 
hypogammaglobulinemia the clinical, serological and histological profile improved after infusion 
of monoclonal anti-HBs (34). Furthermore HBsAg-anti-HBs complexes have been used as 
therapeutic vaccines in chronic hepatitis B patients resulting in an enhanced HBsAg specific T 
cell response (35). 
II. Virus suppressive drugs 
1. Lamivudine 
Lamivudine is a cytidine dideoxynucleoside analogue which acts as a chain terminator after 
incorporation in the viral DNA during formation of the (-) and (+) DNA strand. Lamivudine is a 
strong virus suppressive agent that is well tolerated showing minimal side effects during 
therapy for up to 3 years (36-37). Antiviral therapy with lamivudine aims primarily at long-term 
virus suppression leading to reduction of necrosis and inflammation preventing further liver 
damage. Furthermore the strong viral load reduction during lamivudine therapy may restore the 
T-cell response to HBcAg and HBeAg in HBV patients, although this has been found in one 
study only up to date (38). 
Lamivudine monotherapy significantly reduces HBV DNA levels, normalizes ALT levels and 
improves liver histology (36, 39-41 ). Between 15 and 40% of patients at 1-3 yeas of therapy 
obtain the endpoint of seroconversion (36, 39-42). Elevated baseline AL T is the strongest 
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predictor of HBeAg seroconversion (40,43). Although prolongation of therapy up to 3 years 
increases the HBeAg seroconversion rate to 40% a similar increased occurrence rate of 
lamivudine resistant mutants is observed up to 57% at 3 years (37). A point-mutation in the 
YMDD motif of the HBV polymerase gene, replaces the methionine by either a isoleucine 
(M5521) or valine (M552V), which considerably reduces the sensitivity of HBV to lamivudine 
(44). The YMDD motif is located in the highly conserved domain C, encoding for the 
triphosphate binding and catalytic region of the viral polymerase. A third mutation, with cross-
resistance to famciclovir, has been described in the C domain replacing leucine to methionine 
(l528M) and is linked to M552V (45-46). 
Although the durability of HBeAg seroconversion following lamivudine monotherapy is 
suggested to be comparable to IFN therapy, reports on this are contradictory (47-51). Whereas 
in some reports a sustained response is seen in around 80% of patients, single-centre studies 
show a relapse in nearly 50% of patients during long-term follow up (49-50). Since lamivudine 
is unable to reduce the amount of ccc-DNA in vitro, the persistence of ccc-DNA in the nuclei of 
the hepatocytes during therapy is probably responsible for relapse of viral replication after 
cessation of therapy (52). 
2. New nucleoside analogues 
a. Famciclovir, a deoxyguanosine nucleoside analogue, is the oral pro-drug of penciclovir 
and has been investigated in a phase 3 clinical trial. Monotherapy for 1 year results in a 
significant histologic improvement. However famciclovir has only a modest HBV suppressive 
activity which is clearly inferior to lamivudine monotherapy (53). Famciclovir may have a role 
in combination therapy with other nucleoside analogues in HBV (54). 
b. Lobucavir is a guanosine analogue, showing a 2-4 log reduction in HBV DNA after 4 
weeks of therapy. However clinical studies in HBV have been terminated prematurely 
because of potential carcinogenic effects of lobucavir after a prolonged exposure in small 
animal models (55). 
c. Adefovir-dipivoxif (bis-POM PMEA), is a acyclic nucleotide analogue of dAMP, showing 
potent antiviral activity against HBV (55). Twelve weeks of Adefovir causes a 4 log reduction 
of HBV DNA levels and enhances the HBeAg seroconversion rate compared to placebo (56). 
Moreover Adefovir shows antiviral activity against lamivudine resistant strains and may be 
effective in the treatment of lamivudine resistant HBV patients (57). However renal toxicity, 
probably dose-dependent, has become a safety problem after a prolonged period of time. 
This has made it necessary to reduce the dose of Adefovir from 60 to 30 and finally 10 mg 
daily. 
d. Entecavir is a carbocyclic deoxyguanosine analogue currently under investigation in phase 
Ill trials. It shows potent anti-HBV activity at a low dose, a 2.42 mean log reduction in HBV 
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DNA levels at 4 weeks of therapy was observed (58). Entecavir is the only nucleoside 
analogue with potential effect on ccc-DNA-(59). 
e. Emtricitabine, 5 fluorothiacytidine ((-) FTC), is the 5-fluorinated derivate of lamivudine and 
is currently under investigation in phase 1111 trials. In a dose escalating study therapy for 24 
weeks was well tolerated and the maximal dose (200 mg) showed a median 3 log reduction 
of HBV DNA levels at week 24 (60). 
Ill. Combination therapy 
Combining immunostimulatory and virus suppressive drugs may theoretically increase the 
degree of virus suppress1on and elimination. The efficacy of combination therapy of standard 
IFN and lamivudine in HBV has been investigated in several trials in the past (40, 61-63). A 
study on combination therapy in previous non-responders showed a more profound 
suppression of HBV replication during combination therapy, however no therapeutic merit was 
obtained (61). Three large randomised controlled trials on combination therapy in chronic HBV 
have been performed (40, 62-63). In the first 2 studies, evaluating 226 IFN naive and 238 IFN 
non-responders, no significant benefit of combination therapy was observed (40, 62). However 
a per-protocol analysis performed by Schalm et al revealed a significant higher HBeAg 
seroconversion rate following combination therapy (36%) compared to lamivudine 
monotherapy (19%) or IFN monotherapy (22%). Subgroup analysis based on baseline ALT 
levels showed a benefit of combination therapy especially in patients with moderately elevated 
serum AL T levels (40). These encouraging results where confirmed in a more recent study in 
151 HBeAg positive patients treated with 24 weeks of lamivudine-IFN combination therapy or 
52 weeks of lamivudine monotherapy (63). Combination therapy significantly increased the 
HBeAg seroconversion rate compared to lamivudine monotherapy (33% versus 19% 
respectively) (63). 
A more detailed study on combination therapy of lamivudine and IFN in HBV seems to be 
worthwhile. In addition we have studied the effect of addition of anti-HBs in lamivudine treated 
patients. 
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Objectives of the study: 
1. To evaluate the effect of combination therapy of virus suppressive (lamivudine) and 
(possible) immuno-modulatory agents (anti-HBs or recombinant alpha-IFN) in chronic 
HBV on virus suppression and elimination. 
2. To study the infiuence of baseline host immune reactivity (marker serum AL T) on 
response and durability of response following mono- and combination therapy of IFN and 
lamivudine in chronic HBV. 
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Introduction 
Considering the limited efficacy of the current drugs registered for chronic hepatitis B (HBV) 
lamivudine and interferon-alpha (IFN), the search for new anti-virals or combination therapy 
aiming at different antiviral targets is ongoing. In chapter II we report on the use of antibodies 
to HBV-proteins (anti-HBs) either alone or in combination with lamvudine or interferon. Anti-
HBs has proven its value in the prevention of post-liver transplantation HBV reinfection of the 
graft, post-exposure prophylaxis after needle stick injuries and prevention of vertical 
transmission in neonates of HBV positive mothers. The formation of HBsAg-Ab complexes 
neutralizes circulating HBsAg, preventing the transfer to other hepatocytes. In addition, 
theoretically, the formation of HBsAb-HBsAg complexes may enhance the antibody-
dependent cellular cytotoxicity. We studied two different antibodies!, the polyclonal hepatitis 
B immunoglobulin (HBig) and Tuvirumab, a human monoclonal preparation of the lgG1 
subclass, directed against the confirmational epitope the a-determinant, produced by a 
transfectoma cell line (MAb). The advantages of the MAb over HBig are the reduced costs, 
unlimited availability and higher affinity for HBsAg shown in preclinical pharmacological 
studies, on the other hand the risk of selecting immune escape mutants is increased. 
We participated in a large multicenter phase II trial investigating the safety and efficacy of the 
MAb as monotherapy or in combination with standard IFN. This trial was stopped 
prematurely due to side effects that were suspected to be immune complex mediated. Only 
15 patients were included at that time of which ten had received the MAb as mono or in 
combination therapy. The results are presented in the first part of this chapter. No 
conclusions about efficacy could be drawn, although various degrees of HBsAg clearance 
were shown. 
Reducing the HBsAg load before administration of anti-HBs could theoretically significantly 
increase the neutralizing efficacy of anti-HBs. We designed two phase II pilot studies using 
lamivudine pretreatment to obtain maximal virus suppression (HBV DNA negativity by 
hybridization assay) before adding anti-HBs (MAb or HBig). The studies aimed to investigate 
the tolerability and neutralizing efficacy of both preparations in chronic HBV patients with low 
level viral replication. The functional activity or "neutralizing efficacy" of both preparations in 
vitro was measured with an inhibition-neutralization assay. In the first study six lamivudine 
treated HBV DNA negative patients received HBig (chapter 11.2). The dosing was based on the 
amount of HBig given to prevent allograft reinfection after livertransplantation. We encountered 
difficulties and low reproducibility with the standard HBsAg and anti-HBs quantification tests. 
Experimental EIA's were designed for more reliable quantification. 
In the second study, started subsequently, the MAb was given in a dose-escalating schedule to 
reduce the risk of immune complex mediated side effects to nine lamivudine treated chronic 
HBV patients. In two out of nine patients repeated infusions with MAb led to serum sickness 
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like syndrome. One was withdrawn form the study, the other eight were evaluable. EIA 
procedures were designed to accurately measure free MAb levels, free HBsAg and MAb in 
MAb-HBsAg complexes. Chapter 11.3 focuses on these laboratory methods. 
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Chapter 11.1 
Abstract 
Background: In this study the safety and efficacy of a monoclonal anti-HBs, Tuvirumab (MAb), 
were investigated. Tuvirumab is a human monoclonal antibody recognizing the stable 'a'-
determinant of the HBsAg. 
Methods: We included 10 chronic hepatitis 8 patients: four received monotherapy, and six 
combination therapy with interferon alpha 2b. 
Results: Because the development of insoluble [HBsAg-HBsAb] complexes led to adverse 
events, the MAb dose had to be reduced in seven patients. In nine patients treatment was 
stopped prematurely because of lack of efficacy, i.e. neutralization of HBsAg in serum. 
However, temporary HBsAg levels were reduced by at least 50% in all patients, in three 
patients receiving combination therapy, background levels of HBsAg in serum were reached. A 
loss of serum HBV-DNA was seen in three patients in the combination group, followed by 
HBeAg seroconversion in two patients. 
Conclusions: We conclude that MAb was not effective in achieving primary efficacy as 
assessed by neutralization of circulating HBsAg. Whether a combination of Mab with an 
antiviral agent that reduces the HBsAg load -and therefore minimizes the risk of adverse 
events- may result in clinical efficacy should be investigated. 
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Introduction 
Only a minority of hepatitis B patients benefits from current treatment strategies. Standard 
alpha interferon (IFN) therapy is effective in about one third of the patients; prolongation 
increases the response rate to a maximum of 40% of patients (1, 2). The respond rate 
depends mainly on baseline characteristics (3). Although lamivudine results in serological, 
biochemical and histological improvement in 60-70% of patients, viral clearance is achieved in 
only 16% of patients at 1 year of therapy (4, 5). Prolongation of lamivudine therapy beyond 1 
year is hampered by the increasing occurrence of lamivudine-resistant mutants, reaching 50% 
after 2 years (4, 6). Although lamivudine and interferon monotherapy clearly has a role in 
antiviral therapy for chronic hepatitis B (CHB), their present therapeutic achievements leave 
sufficient room for the development of new therapeutic strategies. 
The efficacy of hepatitis B immunoglobulin (HBig) in the passive immune prophylaxis of 
orthotopic liver transplant (OL T) patients has been reported (7, 8). In a vaccination trial it has 
been shown that [HBsAb-HBsAg] complexes enhance the proliferative response of human 
HBsAg-specific T-cell clones, resulting in a therapeutic effect on chronic hepatitis B infeclion 
(9). Since immunotherapy in CHB with passive immunization with anti-HBs, was attempted by 
Reed et al using polyclonal HBig (1973) and with monoclonal antibodies by Lever et al (1987), 
no trials of anti-HBs have been performed for the treatment of CHB (10, 11). We therefore 
attempted immunotherapy with MAb in the ten patients reported here. 
Tuvirumab (MAb) is a human monoclonal antibody of the lgG 1 subclass. It is produced by a 
transfectoma cell line, a recombinant mouse cell line (SP2/0) which is transfected with the 
genetic material of a human B lymphocyte of a HBV-vaccinated patient. Regarding binding site 
and binding affinity with HBsAg, Tuvirumab is identical to OST 577, produced by a "trioma" cell 
line, for which clinical pilot studies were performed in OL T patients (12, 13). Both antibodies 
have the same genetic code from the same peripheral blood lymphocyte. MAb recognizes the 
'a'-determinant of the hepatitis B surface antigen. The 'a'-determinant is the most stable part of 
the hepatitis B virus and one of the major neutralizing epitopes. Anti-'a' antibodies are 
protective against almost all known subtypes of the hepatitis B virus (14, 15). The binding 
activity of MAb is 200-fold higher compared with serum-derived polyclonal antibodies (HBig) 
(16). 
In a phase II trial, the safety and efficacy of MAb were investigated. The trial was stopped 
prematurely after 10 patients had been treated with the monoclonal antibody for at least 4 
weeks. The results are presented here. 
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Patients and Methods 
Patients 
Fifteen patients, eight IFN nonresponders and seven IFN naive, were included in this trial after 
giving their informed consent. All patients were above 18 years of age and suffered from 
chronic hepatitis B, defined as HBsAg and HBeAg positivity in serum lasting for at least 6 
months, increased AL T (50-400 U/1) for the last 6 months before study entry, detectable serum 
HBV-DNA (liquid hybridization test), and a histological diagnosis of chronic hepatitis (portal 
inflammation, hepatocyte necrosis). 
Exclusion criteria were: Asian origin, pregnant or lactating women, detectable serum HBeAb, 
co-infection with HAV, HCV, HDV, HIV, fulminant, alcoholic or drug-induced hepatitis or 
decompensated liver disease. For safety reasons, patients were not included if there was a 
history of periarteriitis nodosa, serum sickness, psoriasis, creatinine >1.5 times upper limit of 
normal, proteinuria, micro-hematuria, major organic dysfunction or contraindication for 
interferon. 
Medication 
Patients were stratified for previous IFN therapy and randomly assigned to one of the 
following groups: 
• MAb treatment group (n= 4) 
• MAb + IFN treatment group (combination group) (n= 6) 
• IFN treatment group (only IFN naive) (n= 3) 
• Untreated control group (only IFN nonresponders) (n= 2) 
Interferon cx-2b (lntronrM A, Schering-Piough) was given according to the standard regimen, i.e. 
5-10 MU tiw intracutaneously for 16 weeks, and was not administered on the same day as 
MAb in the combination group. 
MAb is a lyophilisate, which has to be reconstituted with 1 0-ml sterile water before 
administration. After reconstitution, the drug was given intravenously in 250 ml 0.9% NaCI over 
a 30-min period. 
During the first 2 weeks (escalation phase) MAb was given every 2-3 days according to a fixed 
dosing schedule: 20mg-20mg-40mg-40mg-80mg-80mg (20 mg Mab corresponds to about 
360.000 IU anti-HBs HBig). The dosing schedule was based on safety and efficacy data 
collected in a pilot study with OST-577 (14). The dose escalation should result in a step-wise 
reduction of the HBsAg serum level and should therefore minimize potential adverse events 
caused by the formation of insoluble [HBsAg-HBsAb] complexes. The aim of this escalation 
phase was to neutralize circulating HBsAg, resulting in free circulating anti-HBs. 
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In week 3, the maintenance phase, dosing was individualized in order to maintain free anti-HBs 
levels in the blood. In this phase anti-HBs serum levels were measured every 2 weeks. Further 
MAb doses were administered depending on the anti-HBs levels, according to the following 
schedule: 
• serum anti-HBs level >5~glml (corresponds to about 90 000 IU/1 HBig): no further MAb 
administration for the next 2 weeks; 
• serum anti-HBs level >1 ~g/ml (corresponds to about 18 000 IU/1 HBig) but <5~g/ml: 
single dose of 80 mg MAb or of the individual maximum tolerated dose (MTD, see critical 
events) for the next 2 weeks; 
• serum anti-HBs level <1 ~g/ml: 5 doses (every 2 days) of 80 mg MAb or of the MTD for the 
next 2 weeks. If free serum anti-HBs levels were not reached after this frequent dosing, 
treatment was stopped for feasibility reasons. 
Critical events 
According to the above-mentioned pilot study with OST -577, it was anticipated that the 
development of adverse events in patients receiving MAb would be mainly related to the 
formation of insoluble [HBsAg-HBsAb] complexes. For safety reasons critical events were 
defined: anaphylactic reactions type I, cardiovascular reaction during or within 3 hours after 
infusion (shock index >1.2, hypertension), generalized dermatological reactions, severe 
arthralgia, shaking chills/rigors, increase in body temperature >1.5'C (2.5'F). The following 
laboratory parameters were considered critical adverse events: micro-hematuria, proteinuria, 
serum creatinine and urea >150% of initial value, a relevant decrease in serum albumin or an 
increase of serum ALT 5x higher initial value or >800 IU/L. 
If critical events occured during the therapy, MAb dosing was stopped until event resolved, and 
afterwards therapy was continued with a 50% reduced dose, which was considered the 
individual maximum tolerated dose (MTD). Frequency of dosing of MTD was as described 
above. 
Laboratory Methods 
The primary endpoint of the study was the development and maintenance of free anti-HBs 
levels. Secondary, reduction of HBsAg and changes in HBV DNA and AL T were measured. 
All serum samples were stored at -20'C, and HBV markers were assessed centrally. HBV-
DNA was quantified by liquid hybridization (Digene-Murex, UK). HBeAg and anti-HBe 
(qualitatively) were measured using ENZYMUN™ tests (Boehringer Mannheim, Germany). 
Anti-HBs (~g/ml) was detected with a specific double-antigen ELISA (enzyme-linked 
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immunosorbent assay) using biotinylated wild-type HBsAg, which was immobilized on a 
streptavidin-coated tube, as the solid phase. The bound antibodies were detected by binding to 
a horseradish peroxidase conjugated wild-type HBsAg catalyzing the formation of a colored 
product (ENZYMUN"' tests, Boehringer Mannheim, Germany). HBsAg (U/ml) was measured 
by a standard MEIA (microparticle enzyme immuno-assay) (Abbott IMx System). A monoclonal 
HBsAg-antibody that specially binds HBsAg from serum is immobilized to microparticles. The 
bound HBsAg is detected with biotinylated polyclonal goat anti-HBs and a polyclonal rabbit 
anti-biotin antibody conjugated with alkaline phosphatase is catalyzing the formation of a 
fluorescent product. 
The study was performed according to good clinical practice guidelines and the Declaration of 
Helsinki. All local Medical Ethics Committees approved the protocol. 
Results 
Fifteen patients were included in the trial: ten received MAb (four monotherapy and six 
combination therapy with interferon). Baseline characteristics are listed in table 1. 
Table 1 
Baseline characteristics of patients. Data are expressed as median (min~max). 
IFN naive/ 
nonresponders 
Age (yr) 
Gender(m/f) 
HBsAg {U/ml) 
HBV DNA (pg./ml) 
ALT(U/1) 
.. protocol violator 
Safety 
MAb MAb + IFN 
treatment group treatment group 
113 3/ 3 
55 {39-63) 39 (19-46) 
410 412 
36,750 {1,740-72,000) 2,835 (2,200-22,200) 
2,149 (467-6, 130) 152 (8-5,065) 
90(65-116) 100 (27 .. -199) 
IFN Untreated 
treatment group control group 
310 0/2 
37 {24-48) 29 (28-30) 
211 111 
43,200 (6,200-73,000) 3,550 (900-6,200) 
3,755 (2,641-33,220) 556(67-1,045) 
166 (144-199) 132 (34 .. -230) 
No drug-related serious adverse event was observed. A summary of all adverse events 
probably or possibly related to MAb is demonstrated in table 2. Eight out of ten patients 
experienced adverse events probably related to the administration of MAb. In seven patients, 
four patients in the MAb group and three patients in the combination group, critical adverse 
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events occurred. Shaking chills/rigors partially combined with fever was reported 5 times for 
three patients, one in the combination group and two in the MAb group. Proteinuria and 
micro-hematuria were reported for three patients, two in the combination group and one in 
the MAb group. Flu-like syndrome was reported twice for one patient in the combination 
group. Shaking chills/rigors, fever and flu-like syndrome resolved within hours after infusion, 
one patient received an H2-antagonist and in some cases paracetamol was used. Proteinuria 
and micro-hematuria resolved within a few days after withdrawal of therapy. According to the 
study protocol, all seven patients were re-challenged with a 50% reduced MAb dose (MTD) 
after the events resolved. No further critical event was observed. 
Table 2 
Summary of adverse events probably or possibly related to MAb. 
AE critical AE criticaiAE totaiAE 
(no measures) (dose reduction) (temp. stop of treatment+ 
dose reduction) 
Chills 3 0 4 
Fever 0 2 0 2 
Abdominal pain 0 0 
Tinnilus 0 0 
Arthralgia 0 0 
Syncope 0 0 
Dyspnoea 2 0 0 2 
Flu-like syndrome 0 2 0 2 
Lower back pain 0 0 
Leucopenia 0 0 
Proteinuria 0 3 4 
Micro-hematuria 0 0 
Efficacy 
MAb was administered over a period of 27-59 days. In eight out of ten cases MAb was 
discontinued prematurely according to the study protocol, because a frequent treatment of 5 
infusions in 2 weeks during one cycle in the maintenance phase did not result in free anti-HBs 
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serum levels. One patient was withdrawn from further treatment as scheduled prematurely; no 
free anti-HBs was detectable. Seven of these eight patients received a reduced MAb dose 
(MTD) due to critical events: 40 mg (n=3) and 20 mg (n=4). In two patients the administration 
of Mab was withdrawn prematurely because the study was stopped, in one patients anti-HBs 
was detectable. 
Thus, none of the patients had a sustained clearance of serum HBsAg with the described dose 
regimen. In nine out of ten patients treated with MAb the treatment was stopped prematurely 
because free anti-HBs levels could not be achieved. 
50 100 150 200 250 300 350 
days after first dose 
Figure 1 HBsAg levels (U/ml) measured before start of therapy, at day 14, 27, the end of treatment and end of follow up after 
administration of MAbin the monotherapy (•) or combination therapy (x) group. 
HBsAg levels were reduced by at least 50% in all ten patients during MAb treatment in both 
groups (monotherapy and combination). Figure 1 shows the individual HBsAg curves. In 
three out of six patients in the combination group HBsAg levels were transiently decreased to 
background levels on various occasions, coinciding with free anti-HBs levels in the serum. A 
relapse of HBsAg above pre-treatment levels after stopping treatment was observed in two 
patients in the MAb group. The relative changes of HBsAg serum levels for these ten 
patients at the end of therapy and end of follow-up (EFU) are demonstrated in frgure 2.1n the 
IFN and untreated control group HBsAg levels fluctuated considerably. A temporary drop by 
at least 50% was observed in two out of frve patients, while in another patient HBsAg 
increased by 100%. 
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Figure 2 The percentage change in HBsAg at the end of follow-up (EFU) and the maximal (max) change in HBsAg (U/ml) per 
patient in the monotherapy (MAb) and combination (MAb +IFN) group. In 7 patients HBsAg levels increased again at the 
EFU, in 3 patients minimal HBsAg levels were reached at the EFU. 
With respect to the HBV-DNA levels, three patients in the combination group exhibited a loss 
of HBV-DNA after about 1 week, which was maintained until the end of follow-up, i.e. 8-46 
weeks after start of treatment, IFN was continued in all cases during this period. HBeAg 
seroconversion was seen in two of these three patients. More than 50% reduction of HBV 
DNA was observed in the other three patients treated with combination therapy. In the other 
treatment groups no clinically relevant changes in HBV DNA levels were observed.AL T 
decreased by 30% in the patients treated with MAb, which implies normalization of AL T in 
two out of ten patients, one patient treated with combination therapy group and one with 
monotherapy. No clinically relevant changes in AL T were observed ·,n the untreated and IFN 
treated patients, which was expected considering the short observation period. 
Discussion 
The way of action of passive immunization in hepatitis B patients is only partially known. 
Monoclonal or polyclonal antibodies bind HBsAg, i.e. virions, filaments and spheres that are 
circulating as free particles in the blood or that are presented at the surface of cells. 
Consequently, the infection of non-infected cells via circulation should be inhibited. This 
assumption is supported by results generated during the administration of HBig in OL T 
patients and by results of HBig treatment for interruption of vertical transmission of the virus 
in neonates of HBsAg-positive mothers and after needle-stick injuries (7-8, 17, 18). 
Antibodies might have an indirect effect on cellular immune response via ADCC (antibody 
dependent cellular toxicity) by binding and activation of NK cells, or other so far only 
incompletely understood mechanisms. This hypothesis is supported by results from a 
vaccination trial, in which the administration of [HBsAg-HBsAb] complexes resulted in 
enhanced proliferative response of human HBsAg specific T-cell clones, producing a 
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therapeutic effect in CHB patients (9). The concept of immune complexes acting as a strong 
immune stimulus for humoral immunity is further supported by experimental work (19). 
Furthermore, coating of HBV-infected hepatocytes may stimulate the leucocyte-mediated 
phagocytosis (opsonization) (20). In vivo and in vitro (mice model) lgG-anti-HBs can 
stimulate T -helper cells to produce lymphokines, which promote antibody synthesis by 
autologous B-lymphocytes (21). In chronic hepatitis B patients, excess of circulating HBsAg 
may paralyze the immune system, enabling the virus to survive (high dose tolerance 
induction). A reduction of serum HBsAg therefore might result in a reactivation of the 
endogenous immune system (15). 
In this trial the most important finding as to efficacy was that sustained clearance of serum 
HBsAg was not achieved in any of the MAb-treated patients using the described dose regimen. 
In nine out of ten patients treated with MAb the treatment was stopped prematurely because 
the primary goal to reach and maintain a status of free anti-HBs levels could not be achieved. 
On the other hand, it could be shown that MAb recognized and cleared HBsAg from the serum 
to various degrees. Only in the combination therapy group serum HBsAg decreased transiently 
to background levels in three patients. Theoretically, this may also reflect a lower production of 
HBsAg particles because of a reduction of infected hepatocytes in these patients. However, in 
case of stimulation of the cellular immune system, one would expect an elevation of serum 
transaminases. None of the ten patients treated with MAb showed a peak in transaminase 
activity during the treatment or follow-up. 
Only in the combination group serum HBsAg was decreased transiently to background levels 
in three patients. However, it has to be noted that these three patients had relatively low 
pretreatment HBsAg levels. In general, patients with lower baseline HBsAg levels had a better 
response. Therefore, an additional effect of IFN on HBsAg serum levels in the combination 
group, especially in the first weeks of therapy, is unlikely. 
With respect to HBV-DNA, however, it seemed that the combination of MAb with IFN is clearly 
superior to each compound alone. Only in the combination group three patients showed a 
sustained loss of HBV-DNA. In two of these, this was even combined with a HBeAg-
seroconversion when the study was stopped, about 8 to 46 weeks after start of treatment. 
Since IFN treatment was continued in all cases, even if MAb treatment was stopped 
prematurely, it is not possible to discern the relative contribution of the two compounds to this 
positive development, i.e. it cannot be ruled out that this simply reflects the well known effect of 
IFN. 
The critical adverse events seem to be caused by the development of insoluble [HBsAg-
HBsAb] complexes after MAb infusion. This indicates again that the antibody is highly effective 
in binding the antigen and furthermore that the chosen dosing schedule was not sufficient in 
terms of a safe neutralization of HBsAg. There was no predictor for the development of these 
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critical events. However, it is likely that after reduction of HBsAg following MAb administration 
the amounts of antigen and antibody draw near an "equivalence range", combined with an 
increased risk of development of insoluble antigen-antibody complexes. 
'Mth respect to the very limited sample size and treatmenVobservation period, it is obviously 
not possible to judge whether the described effects on serum markers of CHB could potentially 
be translated into clinically meaningful results if the treatment could be maintained by the use 
of an alternative regimen. The most appropriate approach appears to be a substantial 
reduction of HBsAg before initiating the MAb treatment and a maintained blocking of viral 
transcription, e.g. by pre- and concomitant treatment with nucleoside analogues. This may 
prevent the occurrence of insoluble [HBsAg-HBsAb] complexes and may facilitate the 
complete clearance of HBsAg and viral particles by the monoclonal antibody. 
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Abstract 
Background: In view of the limited efficacy of lamivudine monotherapy for chronic hepatitis B 
(HBV), combination with other drugs seems logical. Intravenous neutralization of circulating 
HBsAg by specific hepatitis B immunoglobulin (HBig) has been shown to protect hepatocytes 
against (re-)infection with HBV in the setting of liver transplantation and post-exposure 
prophylaxis. Large controlled vaccination trials have revealed that HBV can be prevented by 
HBig therapy in the majority of newborns after perinatal infection. A benefit of anti-HBs in HBV 
patients has so far only been investigated in 3 small studies. In this pilot study we investigated 
the effects of polyclonal i.v. HBig (Hepatect®, Biotest) administration in HBV patients. 
Methods: Six liver biopsy-proven HBV patients, all on lamivudine treatment and HBV DNA-
PCR negative, were investigated. Pre-treatment HBsAg levels varied between 120 and 9760 
ng/ml. On day 1 10.000 I.U. HBig was given, followed by 10.000 I.U. once, twice or three times 
on day 29. Long-term follow-up lasted at least 4 months. HBsAg and anti-HBs were measured 
quantitatively by standard MEIA and also by an experimental EIA. In vitro neutralization of 
HBsAg by Hepatect was mimicked in an "inhibition in solution assay". 
Results: Complete neutralization of HBsAg by HBig in vitro was possible, 50% inhibition 
concentrations varied between 100-250 IU/1 HBig with HBsAg levels of 68 and 120 ng/ml. No 
HBig-related side effects were observed. In 2 patients with low pretreatment HBsAg levels 
HBsAg reached levels below the detection limit of the assay, which persisted a maximum of 31 
and 7.5 hours, respectively. Peak anti-HBs concentrations were 5100 and 4648 IU/1. In the 
other 4 patients, with higher pre-treatment HBsAg levels, HBsAg concentrations in serum 
hardly changed. For the whole population, the drop in HBsAg did not reach statistical 
significance. However, in 4/6 patients a further decrease in HBsAg (18%-66%) was observed. 
Conclusions: HBig was well tolerated; however, efficacy was limited due to high HBsAg levels 
in spite of maximum inhibition of virion production. "Neutralization" was achieved only in 2 
patients with low HBsAg levels. Passive immunization in HBV DNA negative patients is not a 
feasible option. This strategy seems only feasible if agents inhibiting both the production of viral 
proteins and Dane particles more selectively, become available. 
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Introduction 
Current treatment strategies for chronic hepatitis 8 virus infection (H8V) including alpha 
interferon and lamivudine monotherapy, have limited efficacy. During 16 weeks of interferon 
monotherapy, around 30% of patients lose HBeAg, which can be increased to almost 40% by 
prolongation of therapy to 32 weeks (1-3). With lamivudine monotherapy sustained H8eAg 
seroconversion is achieved in maximal 20% of patients after 52 weeks of treatment (4, 5). This 
seroconversion is claimed to be durable after withdrawal of therapy, however results are 
inconsistent (6, 7). In general, withdrawal of therapy is accompanied by a relapse of viral 
replication. Prolongation is hampered by the occurrence of lamivudine-resistant mutants in up 
to 50% of patients after 3 years of therapy (7-9). Combination therapy of lamivudine and 
interferon may lead to a higher seroconversion rate among patients with elevated baseline 
transaminases, but the therapeutic benefit has not been established as yet (4). 
Intravenous immunoglobulins have anti-infectious and immunomodulatory effects and are used 
both as prophylaxis against certain infectious diseases and as treatment of various 
autoimmune diseases (10). Hepatitis 8-specific immunoglobulins (H81g) effectively prevent 
post-exposure infection. Furthermore HBig interrupts perinatal transmission and a protective 
antibody titre develops in the majority of newborns after repeated doses (11-14). Long-term 
passive anti-H8s immunoprophylaxis is part of the standard therapy following liver 
transplantation in chronic H8V patients (15-18). Complete virus neutralization with a free 
antibody level in serum prevents clinical reinfection by circulating virions. 
Small studies in HBV patients have shown therapeutic benefit of HBig (H8V clearance) for 
patients with low HBsAg levels (19). Newly developed monoclonal antibodies significantly 
reduced viral load in a trimera-mouse model, indicating active binding of H8V particles and 
removal from serum (20). The infusion of these 2 monoclonal antibodies in HBV patients lead 
to a (temporary) decrease in H8V DNA load and a reduction in H8sAg (21 ). The administration 
of monoclonal antibodies to HBsAg in 2 patients with hypogammaglobulinemia improved the 
clinical, serological and histological profile of these patients (22). 
Antibody-antigen complexes have been shown to enhance viral clearance during long-term 
follow-up by increasing the uptake of complexed H8sAg by macrophages mainly through the 
Fe receptor. This modulation of the antigen presentation by the immune-complexes leads to 
increased T-cell responses and induction of production of pro-inflammatory cytokines (23-27). 
Encouraging in vitro results in hepatoma cells showed the internalization of lgG antibodies in 
hepatocy1es, independent of the Fe receptor, influencing the assembly and secretion of H8sAg 
(28). 
Infusions of hepatitis C virus immunoglobulins (Cicavir®) in chronically hepatitis C virus (HCV) 
infected chimpanzees influenced the HCV replication and in vitro HCV specific antibodies 
seemed to mediate antibody-dependent cellular cytotoxicity (ADCC) (29, 30). 
37 
Chapter 11.2 
Based on these small studies we investigated the feasibility, determined mainly by high costs, 
the toxicity and the effectivity of anti-HBs to obtain a sustained decrease in HBsAg levels in 6 
HBV patients, in a phase II study. To optimize the therapeutic effect of anti-HBs, in this pilot 
study patients were pre-treated with lamivudine to decrease the number of complete virions. In 
case maximum viral suppression was achieved, polyclonal i.v. HBig (HepatectR, Biotest) was 
added. 
Patients and methods 
Study population 
From a cohort of 25 chronic immunocompetent HBV patients treated with lamivudine, 6 
patients were selected on the basis of their therapeutic response to lamivudine (HBV DNA 
levels). All patients had a liver biopsy-proven HBV and HBV DNA negativity (PCR) in 
combination with HBsAg-positivity during lamivudine monotherapy. Reasons for exclusion of 
patients were other acquired or inherited causes of liver disease, other significant medical 
illnesses or conditions which might interfere with the study and contra indications for the use of 
immunoglobulin therapy such as hypersensitivity or allergy to human immunoglobulins. The 
study protocol was approved by the Medical Ethical Committee; all patients gave written 
informed consent. 
Administration of HB/g 
Hepatect is a human polyclonal hepatitis-B-immunoglobulin preparation containing human 
polyclonallgG antibodies against HBsAg with at least 50 I.U. of anti-HBs per ml, mainly of the 
lgG1 and 2 subclass. Before administration 200 ml of the antibody are dissolved in 250 ml of 
5% glucose solution. On day 1 10.000 I.U. (200 ml) was administered intravenously over a 3D-
minute period. The dose is based on the amount of HBig given to prevent liver allograft 
reinfection after orthotopic liver transplantation. If patients tolerated the first dose of Hepatect 
they were randomized to receive 1, 2 or 3 doses of 10.000 I.U., on day 29, to exclude a carry-
over effect of the first dose on day 1. In case of 2 or 3 repeated infusions the doses were given 
12 respectively 8 hours apart. Follow-up lasted at least until 4 months after the last dose of 
Hepatect. 
Detection of HBsAg and anti-HBs 
At screening, on day 1 and day 29 blood samples tor assessment of HBsAg and anti-HBs were 
taken at start, at the end of the Hepatect infusion and 1, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours 
thereafter. In case of 2 or 3 infusions this cycle was repeated after 12 respectively 8 and 16 
hours. Additional samples were taken after the first and second infusions on days 3, 4, 5, 8, 15 
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and 22 and on days 31, 32, 33, 36, 43, 50, 57 and 64 after the first dose. The last sample for 
long-term follow-up was taken 4 to 5 months after the last infusion. 
HBsAg was measured in serum quantitatively by a standard Microparticle Enzyme lmmuno 
assay (MEIA) (AxSYM, Abbott) using a set of standard samples based on the PEl standard 
(Paul Ehrlich Institute). The MEIA uses microparticles coated with mouse monoclonal anti-HBs 
to detect HBsAg. The detection limit of the test is 0.01 PEU/ml, but below 3.13 PEU/ml 
quantification could not be considered reliable. 
In addition HBsAg was quantitated in an experimental EIA performed in Costar EIAIRIA 96-
wells fiat bottom plates (high binding). The plates were coated with monoclonal antibodies 
according to standard procedures. The solid phase of the HBsAg-EIA consisted of human 
monoclonal antibody F4-7B (Biotest Pharma, Dreieich, Germany) and mouse monoclonal 
antibody HBs.OT39 (Organon Teknika, Boxtel, The Netherlands) was used as conjugate. Both 
antibodies, F4-7B and HBs-OT39, are not influenced by changes in the major antigenic region 
("a"-determinant). Wells were incubated with a 100 ~I sample for one hour at 37"C. Samples 
were diluted in buffer (EB) containing PBS with 3% NaCI, 0.05% Tween 20, 0.2% milk powder, 
and 1% normal goat serum. After incubation, wells were washed four times with PBSffween 
(0.05% Tween 20). Subsequently, incubation was continued with biotin-labeled monoclonal 
anti-HBs (1 hour 37"C), avidine-labeled horseradish peroxidase (30', 37°C), and TMB 
substrate (10', room temperature) in succession. Between incubations wells were washed 
extensively with PBS/Tween. The reaction was stopped with 1 N H,SO,. Extinction was read at 
450 nm. Quantification was performed with an alternative standard related to the PEl standard 
for HBsAg. HBsAg levels were expressed in ng/ml, 1 ng/ml corresponds to about 1 PEU/ml. 
Longitudinal screening for HBsAg and human lg/HBsAg immune complexes during therapy 
was performed with solid phase HBs.OT40 and HB.OT42 (mouse monoclonal anti-HBs, 
Organon Teknika, Boxtel, The Netherlands); F9H9, F7-4B (human monoclonal anti-HBs, 
Biotest Pharma, Dreieich, Germany) and sheep anti-Hu-lg conjugate (Amersham) were used 
for detection. All monoclonal antibodies were directed against epitopes on the smallS-protein. 
AxSYM MEIA (Abbott, AUSAB) was used for the quantification of anti-HBs. Solid phase HBsAg 
in this assay is recombinant HBsAg (adw2 and ayw) expressed in mouse L cells (31, 32). 
For comparison of HBsAg levels, samples were tested in the same run. Pharmacokinetic 
samples were tested in the same run per patient. 
Inhibition-neutralization assay 
Efficacy of serum anti-HBs to achieve neutralization was mimicked in an "inhibition in solution" 
assay according to the method described by Heijtink et al (33). Inhibition assays were 
performed with solid phase mouse monoclonal HB.OT40 and HB.OT42, and human 
monoclonal F4-7B as a conjugate. 
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Results 
Baseline characteristics of the six patients and randomization on day 29 are shown in table I. In 
all 6 patients HBV DNA (PCR, detection limit 400 genome equivalentslml (geqlml) based on 
the Eurohep HBV standard) was negative at screening; however at inclusion HBV DNA was 
3.77x103 geqlml (Roche, Amplicor, detection limit 1x103 geq/ml) in one patient without 
evidence of a lamivudine-resistant mutant. In spite of the fact that all patients were HBV DNA 
negative (PCR) during lamivudine treatment HBsAg levels showed a wide variability unrelated 
to the duration of lamivudine therapy; HBsAg at baseline varied from 120 to 9760 nglml (EIA). 
Safety 
The administration of Hepatect was well tolerated and there were no drug-related side-effects, 
in particular there were no symptoms of immune-complex disease. One patient with a pre-
existent low blood pressure experienced mild hypotension while sleeping without any 
complaints before administration of the third infusion on day 29. Other observed adverse 
events were headache (n=2), flu (n=2), anaemia (n=1), cystitis (n=1) and eczema (n=1). They 
were not considered to be drug-related. 
Table 1 
Baseline characteristics 
Pt. race gender Age (yrs) lamivudine (months) HBV DNA geq/ml HBsAg ng/ml 
Chinese m 50 115 Neg 123 
2 Chinese m 31 8 Neg 120 
3 African m 37 3 Neg 2480 
4 African 21 4 Neg 4800 
5 Turkish m 27 5 3,77x103 9760 
6 Indonesian m 37 6 Neg 2320 
1HBV DNA at screening (within 6 weeks before start of therapy) measured by PCR. detection limit 400 geq/ml (based on the 
Eurohep standard) and if positive by Quantitative PCR, detection limit 1000 geq/ml (patient 5 before start of therapy). 
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Anti-HBs 
Neutralization of HBsAg by HB/g in vitro 
Pre-treatment serum from 3 patients (patients 1, 4 and 6), representing low (215 ng/ml), high 
(4200 ng/ml) and moderate (2880 ng/ml) HBsAg levels, respectively, at screening were tested 
with the inhibition assay. Pre-treatment samples of these patients were diluted and 68, 120 and 
68 ng/ml HBsAg respectively were pre-incubated with increasing amounts of Hepatect, up to 
5000 lUll. At HBsAg serum concentrations between 50-100 ng/ml, the 50% inhibition 
concentrations (ICso) per patient, which can be seen in figure 1, varied between 1 00 and 250 
IU/1 of Hepatect. In vitro nearly 100% inhibition of HBsAg-binding to solid phase anti-HBs in EIA 
was observed in all three cases. However 1250, 5000 and 2500 IU/1 respectively were needed 
to neutralize 68, 120 and 68 nglml HBsAg in this assay (Fig 1). Theoretically between 240 and 
544 ng/ml HBsAg can be neutralized with 10.000 IU/1 Hepatect, according to these 
measurements. 
100 
Percentage inhibition 
F-500---
500 l == -=--=--~ f-
r 
1Pt6 Pt1 Pt41 50 c_.c:c_ _ ,_,_,____,:.c--'J. 
68 68 120 
Hepatecl in IU/1 HBsAg (ng/ml) 
Figure 1 Dose-response curve of neutralizing efficacy of HBig in three chronic hepatitis 8 patients (left part). Pretreatment serum 
samples were diluted and the concentration of HBsAg in the assay was 68 (•), 68 (+)and 120( ll) ng/ml. The figure 
illustrates that between 100 and 250 IU/1 of HBig are needed to have 50% inhibition of 68 and 120 ngfml HBsAg (IC50) in 
this assay. The right part shows the amount of HBig (IU/1) needed for nearly complete inhibition. 
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Pt. neutralization after peak anti-HBs lUll randomization day 29 neutralization after peak anti-HBs IU/1 
first dose (HBsAg after first dose (no. of doses) second dose(s) (HBsAg after second dose(s) 
negativity in hrs) negativity in hrs) 
0 464 3 7,5 4.648 
2 4,5 328 3 3,5 and 31 5.100 
3 0 156 2 0 324 
4 0 185 1 0 179 
5 0 14 2 0 23 
6 0 10 1 0 9 
Table 2 
Neutralizing effects of He pat eel in hours and peak anti,HBs levels per patient after the first dose on day 1 and after the dose(s) on day 29. 
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Figure 2 The effect of HBig on HBsAg levels and the loading of anti~HBs on HBsAg after the first dose are 
shown. HBsAg (first two bars in both figures) and antl-HBs (third striped bar in both figures) 
quantification for two patients with low (upper panel) and medium (lower panel) pretreatment 
HBsAg levels after the first dose of HBig. All samples were tested in the same dilution. Epitopes 
corresponding to F9-H9 and F4-78 are located within and outside the major antigenic region of S-
protein ("a"-determinant). In patient 2 HBsAg reached background levels after the first HBig 
infusion for 12 hours. In contrast HBsAg levels in patient 3 hardly changed, the loading of HBsAg 
particles with anti-HBs (Hu-lg) however was clearly detectable at the end of infusion (t=O.Sh) and 
decreased to baseline on day 4. Pre-T=pre-treatment, h=hours, d=days. 
Cha ter II 
Neutralizing efficacy during treatment 
Table II summarizes the effects on HBsAg and peak anti-HBs levels per patient after the first 
dose on day 1 and the other dose(s) on day 29. Only in cases 1 and 2, both patients with very 
low pretreatment HBsAg levels (123 and 120 ng/ml, respectively) was neutralization possible. 
Thirty minutes after start of the infusion background levels of HBsAg were reached and 
maintained in patient 2 on day 1 for 4.5 hours and on day 29 for 3.5 hours, 31 hours after the 
first and the second infusion; in patient 1 neutralization was maintained for 7.5 hours after the 
second infusion on day 29. Maximum peak concentrations of anti-HBs in the two patients were 
5.100 IU/ml and 4.6481U/ml, respectively (MEIA, AxSYM). 
The short-term effects of HBig in patients 3, 4, 5 and 6 were minimal; no significant changes in 
HBsAg levels could be detected after the Hepatect infusions. Although HBsAg was not 
neutralized, free antibody, probably heterotypical antibody, was detectable in patients 3 and 4 
with peak levels of 324 IU/1 and 184 IU/1. On day 64 a very low antibody level was still 
detectable in patient 3. 
Figure 2 illustrates in two patients with low (upper panel) and medium (lower panel) pre-
treatment HBsAg levels, the changes in HBsAg and the loading of anti-HBs on the surface of 
particles that still bind to the solid phase of the experimental assay (EIA). Although no change 
in HBsAg was observed in patient 3, who had a medium pre-treatment HBsAg level, an 
increase in human lgG (detected with a-Hu-lg) on HBsAg particles was detected 
simultaneously with HBsAg. In the patient with low HBsAg levels, a drop of HBsAg to 
background levels was observed. 
Long-tenn effects of HB/g 
One month after the last infusion no significant decline in HBsAg levels was observed 
(Wilcoxon signed rank), although HBsAg dropped in 4/6 patients. The maximum decrease in 
HBsAg was 34% compared with baseline values. HBsAg levels, measured at the end of follow 
up (EFU) 4 to 5 months after the last infusion, were substantially lower in 4 patients compared 
to pretreatment levels, with a maximum decline of 66%, however this difference was not 
significant (Wilcoxon signed rank) (Fig 3). Only in the 2 patients with very high HBsAg levels no 
change was obseiVed. Serum transaminases were normal during lamivudine therapy in 5 out 
of 6 patients and were not influenced by the HBig infusions. 
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Figure 3 Absolute (left) and percentage (right) change in HBsAg ng/ml per patient before first dose of HBig (baseline), second 
dose of HBlg (day 29), at the end of follow-up (day 64) and 4-5 months after the last infusion with HBig (EOFU) 
(median-}. All samples were measured in the same run with the experimental EIA. No significant changes were 
observed. 
Discussion 
HBig can effectively interrupt the transmission of viral particles between hepatocytes and 
theoretically may have immunostimulatory effects by ADCC. The administration of anti~HBs 
was beneficial in 3 small trials, which included 6 chronic carriers, 15 HBV patients and one with 
2 HBV patients with hypogammaglobunaemia (19, 21, 22). However these promising results 
could not be confirmed in this pilot study, encompassing 6 HBV patients. 
Lamivudine rapidly suppresses HBV replication and about 26% of patients are HBV DNA 
negative by PCR after 6 months of therapy (34). At that time viral protein production of HBeAg 
is reduced by about 80% and a similar trend is observed for HBsAg (35). This is comparable to 
the reduction of HBsAg in IFN responders in whom HBsAg levels are halved after HBeAg 
seroconversion (36). 
We used lamivudine to decrease the amount of circulating HBV and then tried to neutralize the 
remaining circulating virions with HBig in order to prevent infection of regenerating 
hepatocytes. We realized to be hampered by the enormous bulk of non-infectious particles 
despite maximal virus suppression by lamivudine pre-treatment, which significantly hampered 
the efficacy of anti~HBs to obtain and maintain lower HBsAg levels. Furthermore, due to 
depressed viral production hepatocyte turnover seems to be reduced as deducted from 
normalization of serum transaminases. 
Although HBsAg levels obtained in our patients during lamivudine monotherapy were similar to 
patients who have responded to IFN therapy, in vivo, HBsAg neutralization could only be 
reached in 2 out of 6 patients (36). Only in those with very low pre~treatment HBsAg levels, 
HBsAg was undetectable which was maintained only for a relatively short period of time even 
after 30.000 IU of HBig. After a maximum of 31 hours HBsAg levels rapidly increased 
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simultaneously with a decreasing anti-HBs level. In vitro, HBig was capable of complete 
inhibition of HBsAg in sera from three different patients. The inhibition assay demonstrated 
nearly complete neutralization of HBsAg levels between 50 and 100 ng/ml with 5000 IU HBig/1. 
However, very large amounts of HBig would be needed theoretically to cover all epitopes in the 
other 4 patients, with HBsAg levels between 25 to 200 times higher than patients 1 and 2. In 
these patients HBsAg levels showed little variation, even after multiple infusions within 24 
hours. Different subtypes may play a role as well as a high production rate of HBsAg. We 
measured incomplete binding of HBsAg in one patient with medium pre-treatment HBsAg 
levels; anti-HBs/HBsAg complexes were detectable until 4 days after HBig without any change 
in HBsAg load. 
Although on day 64 there was only a small percentage decrease in HBsAg in 4 patients, at the 
end of follow-up a more pronounced although not significant, drop in HBsAg was found for 4 
out of 6 patients. In one case a 66% decrease was reached. Probably this effect is due to 
ongoing suppression of HBV replication during continuous use of lamivudine or natural 
fluctuations of HBsAg titers (35). It may also be an effect on HBsAg secretion as has been 
shown in the hepatoma cells (28). Theoretically, the drop in HBsAg may be explained by (non-) 
specific immunostimulatory effects of antibodies or antigen-antibody complexes, such as anti-
body-dependent cellular cytotoxicity (ADCC), opsonization and stimulation of T -cell 
lymphokines (19, 22, 23, 25, 26, 37). However, despite the formation of immune complexes 
and reduction of serum HBsAg, biochemically there were no signs of enhanced immune 
activation, in contrast to the patients treated with anti-HBs HBsAg-complexes and HBsAg (+) 
bone marrow transplant patients, transplanted with antiHBs positive marrow, who experienced 
a hepatitis flare before viral clearance (23, 38). 
In conclusion the role of passive immunization by HBig in HBV patients pretreated with 
lamivudine seems to be limited due to the relatively high HBsAg levels in the majority of 
patients, despite maximum reduction of viral replication. Although in some of the patients a 
reduced HBsAg level was observed during long-term follow-up, we did not found evidence for 
immune stimulation by HBig. This strategy seems only feasible if agents that inhibit both the 
production of viral proteins and Dane particles more selectively, become available. 
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Abstract 
Background: A human monoclonal anti-hepatitis B antibody preparation (TUVIRUMAB 
(MAb)) was administered 6 times over a 2-week period in a dose-escalating scheme to 
chronic hepatitis B patients pre-treated with lamivudine. 
Methods: We investigated the capacity of the TUVIRUMAB antibody to "neutralize" hepatitis 
B surface antigen in the circulation by means of experimental enzyme-immunoassays. 
Monoclonal antibody conjugates enabled the detection of HBsAg, TUVIRUMAB and 
HBsAg/TUVIRUMAB complexes. 
Results and Conclusions: The results showed that a) TUVIRUMAB was partially able to 
"neutralize" in vitro and in vivo, b) HBsAg/TUVIRUMAB complexes can be traced by assays 
that capture the complex at either its HBsAg or its TUVIRUMAB component, c) the final 
concentration of TUVIRUMAB at the end of therapy varied greatly but seemed to be related 
to HBsAg production at the start of therapy, d) for at least 14 days after discontinuation of 
therapy a minimal HBsAg level could be maintained in the presence of a declining 
TUVIRUMAB titer in patients with less than 3 ~g/ml HBsAg before the start of therapy, e) 
three months after therapy all HBsAg levels had returned to pre-treatment levels and 
TUVIRUMAB had disappeared. This study has set the limits for administration of 
TUVIRUMAB in chronic hepatitis B patients. 
50 
Anti-HBs 
Introduction 
In the majority of patients with chronic hepatitis B and active viral replication, anti-hepatitis B 
surface antigen antibodies cannot be detected by commercial anti-HBs assays. Low levels of 
anti-HBs antibodies were only observed in long-term carriers (1-2). 
In anti-HBs assays of the ELISA type, anti-HBs antibodies are captured by solid phase 
antigen (HBsAg) and detected by enzyme-labeled HBsAg. Alternatively, solid phase anti-HBs 
antibodies, e.g. mouse monoclonal anti-HBs antibodies, may be used in experimental assays 
to capture HBsAg. In a next step, serum anti-HBs antibodies may be bound to this antigen 
and subsequently monitored with an anti-human-lg conjugate. Unfortunately, in some cases 
naturally adhering lg molecules may give rise to an increased background signal at low 
serum dilutions. On the other hand, this test system may be exploited to monitor anti-HBs 
antibodies in HBsAg/anti-HBs complexes by direct application of the HBsAg positive (serum) 
sample under study to solid phase anti-HBs. 
The functional activity of anti-HBs antibodies to cover HBV and HBsAg particles can be 
measured in vitro in an "inhibition in solution assay" (3). In this case the HBsAg and anti-HBs 
antibodies are pre-incubated and subsequently applied to solid phase coated anti-HBs 
antibodies. By measuring residual HBsAg with an anti-HBs conjugate, the inhibiting activity of 
anti-HBs antibodies can be studied. Similarly, artificial HBsAg/anti-HBs complexes may be 
monitored for HBsAg by capturing these complexes with anti-HBs specific antibodies (anti-
idiotypic antibodies). 
In the present study a human monoclonal antibody (TUVIRUMAB) was administered to 
HBsAg-carrier patients with a low level of virus replication due to treatment with lamivudine. 
The infused anti-HBs was expected to bind to plasma HBsAg. HBsAg/anti-HBs complexes 
will remain in the circulation until they are removed by the reticuloendothelial system. An 
assay for TUVIRUMAB enabled us to monitor the fate of HBsAg and TUVIRUMAB in the 
circulation. 
Patients, Materials and Methods 
Patients 
We studied serum samples from eight patients. All patients had HBV-DNA levels below the 
detection limit (1.5 x 106 geq/ml) of the Hybrid Capture assay (Digene Murex) due to 
lamivudine monotherapy. Three patients were HBV-DNA positive (200-5.000 geq/ml) 
according to quantitative PCR (Roche Amplicor). The patients received TUVIRUMAB 
according to the following schedule: 20 mg on days 1 and 3, 40 mg on days 5 and 8 and 80 
mg on days 10 and 12. TUVIRUMAB was dissolved in 250 ml of 0.9% NaCI solution and 
administered by infusion intravenously over at least 30 minutes. Blood samples were taken 
before and during therapy and up to 3 months after therapy. 
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This study was performed in accordance with the principles of Good Clinical Practice. The 
protocol was approved by the institutional review board and all patients had given their 
written informed consent. 
Materials 
A murine monoclonal anti-idiotypic antibody specific for TUVIRUMAB was used for coating 
microliter plates (Costar HIG EIAIRIA; 1 ~g/ml lgG) and as conjugate (biotin/avidin-HRP 
labeling, Amersham). Reference TUVIRUMAB (TUVIRUMAB-r, 16.1 mg/ml) was titrated in 
standard dilutions to obtain a reference curve for quantitation. For control of experiments with 
sera from the TUVIRUMAB treated chronic hepatitis B patients, we used the same batch of 
TUVIRUMAB material that was administered to these patients (stock TUVIRUMAB-p, 2 
mg/ml). 
As solid phase antibodies, mouse monoclonal anti-HBs (HBs.OT39, HBs.OT40; Organon 
Teknika, Boxtel, The Netherlands) and human monoclonal anti-HBs (F4-7B; Biotest Pharma, 
Dreieich, Germany) were used. Sheep anti-Hu-lg horse-radish peroxidase was purchased 
from Amersham (Bucks, UK). 
As reference HBsAg we used Mat.O as in earlier experiments (3-4). As reference HBIG 
preparation we used Hepatect (Biotest Pharma, Dreieich, Germany). 
All samples were diluted in EB-buffer (PBS with 3% NaCI, 0.01% Tween 20, 1% normal goat 
serum and 0.2% milk powder). 
Methods 
The types of experiments were restricted to EIA- procedures with solid phase antibodies 
(monoclonal anti-HBs and anti-TUVIRUMAB). The first incubation was performed with 
TUVIRUMAB, HBsAg or putative HBsAg/TUVIRUMAB complexes. Detection was by 
monoclonal anti-HBs conjugates (biotin/avidin-HRP labeling), polyclonal anti-human-lg-HRP 
(direct monitoring) or anti-mouse-lg-HRP (indirect monitoring) (see figure 1). 
Results 
Anti-HBs quantitation 
The dilution characteristics of the TUVIRUMAB monoclonal antibody preparations on HBsAg 
were similar to but distinct from those of the two polyclonal antibody preparations, Hepatect 
and WHO reference anti-HBs (figure 2). This complicates the quantitation of TUVIRUMAB 
and conversion to IU/1, which relates anti-HBs to the WHO standard curve. 
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Figure 1 Schematic presentation of test procedures. 
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Artificial HBsAgfTUVIRUMAB complexes in the HBsAg assay 
In a pre-incubation step HBsAg was complexed with TUVIRUMAB in titrated amounts. 
Residual HBsAg was detected in the HBsAg assay ("inhibition assay"). Figure 3 illustrates 
the inhibition activity of TUVIRUMAB (80% inhibition) compared to Hepatect (1 00% 
inhibition). Complete inhibition (1 00%) was observed readily with polyclonal anti-HBs 
(Hepatect) but a lower inhibition percentage was found with monoclonal anti-HBs (3). In the 
latter case the particles were not completely shielded by antibodies and thus may bind to 
solid phase antibodies with still accessible epitopes. 
100 
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~ 70 
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• ~ 50 
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Figure 3 Inhibition in solution of reference HBsAg with TUVIRUMAB (•), Hepatect (D.) and two patient pre-treatment samples 
(patients B o, and C A) (test procedure 1). Solid phase mouse monoclonal anti-HBs (HBs.OT40) and conjugated 
human monoclonal F4-7B were used for assaying. Start concentration of Hepatect was 5,000 IU/1; start concentration 
of TUVIRUMAB was 4 jlg/ml. 
Monitoring TUVIRUMAB in artificial HBsAglanti-HBs complexes 
In an earlier experiment we observed that the residual HBsAg in the "inhibition assay" was 
loaded with anti-HBs (4). However, our efforts to confirm the presence of TUVIRUMAB in a 
more specific way using biotinylated anti-TUVIRUMAB antibody were not successful, 
probably due to steric hindrance of biotin. As an alternative we monitored TUVIRUMAB 
antibodies on HBsAg particles with mouse anti-TUVIRUMAB and rabbit anti-mouse-lg 
conjugate (procedure 5). 
Partially neutralized HBsAg or HBsAgiTUVIRUMAB complexes with different HBsAg-to-
TUVIRUMAB ratios were captured with their TUVIRUMAB site on solid phase anti-
TUVIRUMAB (test procedure 2; test procedure 4b). In a pre-incubation step equal volumes of 
HBsAg and TUVIRUMAB antibody (in titrated amounts) were combined. Results as 
represented in figure 4 may be interpreted as follows: In the complex I samples the 
HBsAglanti-HBs ratio was lowest. The solid phase anti-TUVIRUMAB is saturated with free 
TUVIRUMAB (procedure 4a) and a small fraction of the complexed-HBsAg is bound to anti-
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TUVIRUMAB (test procedure 4b). In the complex II sample, half of the HBsAg particle surface 
is covered with TUVIRUMAB. Due to lowering of the TUVIRUMAB concentration there is not 
sufficient TUVIRUMAB to saturate the solid phase. More complexes are bound which gives 
rise to an increased HBsAg signal. In the complex Ill and IV samples the HBsAgffUVIRUMAB 
ratios reached their highest levels and complexed-HBsAg began to decrease. 
An increase or decrease in the detectable amount of HBsAg may thus be explained by 
participation of HBsAgffUVIRUMAB complexes in competition with free TUVIRUMAB for the 
solid phase anti-TUVIRUMAB antibody. 
Monitoring HBsAg and TUV/RUMAB in patient serum during therapy 
Pre-treatment HBsAg levels were compared with end of treatment (day 15; 3 days after last 
80 mg dose) and end of follow-up levels (day 29) by EIA using a non-competing antibody 
(F4-7B) (5). Substantially decreased HBsAg levels were observed at the end of therapy in all 
patients and at the end of follow-up in half of them (table 1). These latter four patients 
presented with low HBsAg levels at the start of therapy. All patients had returned to pre-
treatment HBsAg levels 3 months after treatment (results not shown). 
Using the TUVIRUMAB assay with solid phase anti-TUVIRUMAB antibody and anti-human-
lg as conjugate (test procedure 4) showed that the TUVIRUMAB antibody titer increased 
gradually during treatment. The increase came earlier in time and reached higher levels in 
those with lower pre-treatment HBsAg levels and strongest reduction of HBsAg at end of 
herapy (table 1). 
One of the patients (C) with a low level of HBsAg in pre-treatment serum presented only a 
36% reduction of HBsAg on day 29. This aberrant reduction corresponds well with the limited 
amount of free and complexed TUVIRUMAB antibody detected on day 12-29 with the anti-
TUVIRUMAB assay. It could well be that the substrain of this Chinese patient was 
responsible for an underestimate of the amount of HBsAg detected by our HBsAg assay 
TUVIRUMAB/HBsAg complexes were studied in samples obtained just after infusion of 
TUVIRUMAB had been completed (30' samples). The TUVIRUMAB/HBsAg complexes as 
well as free TUVIRUMAB were bound to solid phase anti-TUVIRUMAB and monitored with 
anti-human-lg conjugate (for TUVIRUMAB) and F4-7B-conjugate (for HBsAg) (figure 5). The 
highest level of complexed-HBsAg was observed in patient H (day 1) who also had the 
highest level of HBsAg in pre-treatment serum in this group of patients. The decrease with 
time in detectable immune complexes in this assay is ascribed to competition between the 
excess TUVIRUMAB and HBsAg-complexed-TUVIRUMAB for binding to solid phase anti-
TUVIRUMAB antibody. Examples of the TUVIRUMAB load of HBsAg particles captured by 
solid phase anti-HBs (HBs.OT40) are illustrated in figure 6. 
Table 1 
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Serum TUVIRUMAB content during therapy in the anti-Tuvirumab assay•. 
Tuvirumab dose and content in serum 
20 mg 40 mg 80 mg 
..... ------·-
. -------·-··-···· 
Pat. HBsAg HBsAg Perc. HBsAg Perc. 1't 2nd 
"' 
2nd 1't 2nd EDT EOF 
code Pee Red. Red. 
A' 0.49 0.02 96 0.02 96 2.40 7.70 10.90 25.60 46.10 36.60 8.80 
8 1.12 0.01 99 0.01 99 0.02 1.00 7.60 11.50 28.20 35.04 7.20 
c 1.76 0.05 97 1.12 36 0.02 0.02 0.05 1.30 11.20 18.52 0.04 
0 2.00 0.08 96 0.18 91 0.14 0.54 3.02 10.22 29.42 35.55 8.60 
E' 2.48 0.04 98 0.07 97 0.03 1.23 5.76 9.60 25.60 3356 8.00 
F 3.84 0.31 92 3.20 17 0.07 0.04 0.22 0.58 7.94 12.93 0.07 
G 8.32 1.31 84 7.36 12 0.11 0.19 0.24 0.79 7.67 16.38 0.21 
H' 19.84 3.93 80 14.08 29 0.27 0.27 0.17 0.35 3.81 8.98 0.18 
Day 15 29 3 5 8 10 12 15 29 
•samples were taken just before administration of each dose of TUVIRUMAB, at the end of therapy (day 15) and at the end of 
follow-up {day 29). HBsAg quantitation (1-Jg/ml) was performed in E!A using F4-7B human monoclonal anti-HBs as capture and 
as monitoring antibody (test procedure 1). Anti-HBs(TUVIRUMAB) in IJQ/ml (test procedure 4). At the end of follow-up (day 29) 
more than 90% reduction of HBsAg was observed in half of the patients (HBsAg and corresponding antibody levels in bold). 
EOT= end of therapy, 3 days after last dose. EOF= end offoJJow-up. • HBV-DNA positive by PCR. 
Complex t Complex Ill 
Figure 4 Monitoring of reference HBsAg in artificial TUVIRUMAB/HBsAg complexes with different HBsAgfTUVIRUMAB ratios: 
complex 1: 1110.000; complex II: 1/1.000; complex Ill: 1/100: complex IV: 1/10. TUVIRUMAB antibodies and 
TUVIRUMAB/HBsAg complexes were captured with solid phase anti-TUVIRUMAB antibodies. HBsAg detection in 
TUVIRUMAB/HBsAg complexes was with human monoclonal F4-78 conjugate {dark grey, test procedure 2); 
TUVIRUMAB was detected with anti-Hu-lg conjugate (Iicht grey, test procedure 4). 
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Figure 5 Monttoring of HBsAg in HBsAgfTUVIRUMAB complexes in serum samples from two patients (patient F and H) treated 
with TUVJRUMAB in a dose escalating schedule. Samples were taken 30 minutes after each intravenous dose 
administration was started. TUVIRUMAB and TUVIRUMAB/HBsAg complexes were captured with solid phase anti-
TUVIRUMAB antibodies in EIA and detected with anti-Hu-lg conjugate (test procedure 4). Complexed HBsAg was 
detected with monoclonal anti-HBs (F4-7B) conjugate (test procedure 2). The last sample was taken at the end of 
follow-up {day 29). Patient F, HBsAg!TUVIRUMAB complexes .6.; TUVIRUMAB A; Patient H, HBsAgfTUVIRUMAB 
complexes o, TUVIRUMAB a) 
5 a 
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Figure 6 TUVIRUMAB detection in HBsAg!TUVIRUMAB complexes formed after infusion of TUVIRUMAB antibodies as seen in 
patient sera (patients Band C) taken just before infusion of TUVIRUMAB antibodies and at the end of therapy (day 
15). HBsAg was detected by mouse monoclonal anti-HBs conjugate (HBs.OT40) (test procedure 2). TUVIRUMAB 
detection was with anti-TUVIRUMAB antibodies and anti-mouse lg conjugate (test procedure S).(Patient 8, 
HBsAg!TUVIRUMAB complexes o; TUVIRUMAB a; patient C, HBsAg!TUVIRUMAB complexes 8, TUVIRUMABA). 
57 
Chapter !1.3 
Discussion 
One of the strategies of immunoglobulin therapy is the formation of antigen-antibody 
complexes that will prevent infectious agents, such as viruses, from entering target cells. 
Furthermore, the formation of complexes promotes the opsonization of these complexes by 
macrophages and other scavenger cells. Hepatitis B immunoglobulin preparations consisting 
of polyclonal anti-HBs are widely used to prevent recurrence of hepatitis B in liver transplant 
recipients (6) and spread of the virus after accidental exposure. Reports on the application of 
immunoglobulin preparations in the therapeutic setting of a chronic hepatitis B carrier are 
scarce (4, 7-10). 
In contrast to the polyclonal antibodies that may act largely as complex forming agents, 
monoclonal antibodies may also react with epitopes with defined functions such as receptor 
binding on cells, penetration into cells, complement fixation and neutralization of infectivity by 
specialized mechanisms. 
In our study population, the replication rate and production of viral particles were depressed 
by long-term use of lamivudine. However, this was not accompanied in all cases by a low 
level of HBsAg at the start of the immune therapy. 
The aim of the present clinical study was to investigate the potency of a monoclonal antibody 
preparation to block hepatitis B epitopes in the circulation in order to prevent the spread of 
the virus to non-infected hepatocytes. The lack of an easily accessible infection system and 
the limited knowledge of the role of small S-antigen-located epitopes in infecting hepatocytes 
(11) hinder the extrapolation of in vitro results to the vivo situation. However, administration 
of human monoclonal antibodies and the search for an immune modulating effect in the 
patient's circulation is one step closer to patient-adapted therapy for prevention of relapse or 
in cases of pending HBeAg seroconversion. An assay that specifically monitors the human 
monoclonal anti-HBs antibodies in the circulation of our patients under treatment enabled us 
to directly detect the antibody in HBsAg complexes. This has not been described before. 
The total period of administration of TUVIRUMAB antibodies was less than 15 days. The 
largest amounts of TUVIRUMAB were given in the last 5 days of therapy (2x80 mg). In two 
cases we found final concentrations of TUVIRUMAB corresponding to the total amount of 
TUVIRUMAB administered in the whole period of therapy. This was observed in patients with 
low pre-treatment levels of HBsAg. This result may be explained by the uncertainty in 
quantitation of TUVIRUMAB at dilutions of 1 to 10 million, the relatively short time in the 
circulation of the larger dose of TUVIRUMAB, the accessibility of TUVIRUMAB in the 
HBsAg/TUVIRUMAB complexes and the long circulatory half-life of a human monoclonal 
antibody in the absence of strong antigen-driven consumption. 
Since over 80% of HBsAg reduction was observed in all patients at the end of treatment and 
a 90% reduction was found for at least 14 days after stop of therapy in half of them, these 
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experiments suggest that the present schedule of TUVIRUMAB administration is suitable for 
optimal blocking of HBsAg and with free TUVIRUMAB in the circulation in patients with less 
than 3 ~g/ml HBsAg. 
The use of a TUVIRUMAB-specific assay to monitor HBsAg and TUVIRUMAB has clarified 
the simultaneous presence of HBsAg and TUVIRUMAB. We now know that the presence of 
TUVIRUMAB, as detected by the anti-HBs assay, may indicate that the antibody is free in the 
circulation or is bound to HBsAg. Similarly, HBsAg reduction as measured in HBsAg assays 
does not exclude the binding of partially complexed HBsAg to the solid phase in our assay. 
In practice, remaining functional groups of importance in the infection process may determine 
whether these antibodies will really block infection or spread of the virus. As long as we are 
unaware of the in vivo neutralizing efficacy of TUVIRUMAB, this study may have helped to 
set the limits of TUVIRUMAB antibodies in relation to the HBsAg load in our chronic hepatitis 
B patients. 
It is expected that under a long-term regimen of lamivudine treatment virus production and 
virus transfer to uninfected hepatocytes is limited. Therefore, criteria for subjecting patients to 
immunoglobulin therapy should not only include a low level of HBsAg production but also the 
regeneration of non-infected hepatocytes. Use of high concentrations of monoclonal antibody 
might create the conditions needed for expansion of uninfected liver cells and prevention of 
virus transfer. 
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Chapter 111.1 
Abstract 
Background: Acute hepatitis A virus (HAV) infection can cause severe hepatitis, especially in 
patients with underlying chronic liver disease. In patients with pre-existing chronic hepatitis B 
(HBV), acute HAV infection can suppress HBV replication. The exact mechanism of HBV 
suppression during acute HAV infection is still a subject of debate. One mechanism may be the 
production of HAV infection-induced cytokines, leading to suppression of HBV replication and 
viral clearance. 
Objective: To evaluate cytokine production and HBV-specific lympho-proliferative responses 
(LPR) during acute HAV infection in a patient with chronic HBV infection-clearing markers of 
active HBV replication. 
Methods: Early detection of a case of acute HAV infection in an HBeAg-positive, HBV DNA-
positive chronic HBV patient treated with lamivudine. Setting: Erasmus University Hospital 
Rotterdam; tertiary referral center. 
Results: At the time of HAV infection a sharp peak in the gamma-interferon (IFN-"{) level 
occurred just before the rise in serum transaminase activity. This was subsequently followed by 
a decrease in HBV DNA and HBeAg below the limit of detection of the assay. However, the 
HBV-specific T-cell response was not modified. After resolution of the acute HAV infection and 
withdrawal of antiviral therapy, HBV replication relapsed. 
Conclusion: The sharp rise in IFN-1 production mediated by the acute HAV infection may be 
pivotal in the suppression of HBV replication in chronic hepatitis B. 
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Introduction 
After acute hepatitis B virus (HBV) infection 5-10% of all adult patients become chronically 
infected; the mechanism of the viral persistence in this minority of patients remains unclear. In 
patients with an acute self-limiting HBV infection a vigorous T-lymphocyte response to the core 
antigen and a weaker response to the surface antigen are observed (1, 2). It is suggested that 
the production ofTh1-type pro-inflammatory cytokines (gamma-interferon (IFN-y), interleukin-2 
(IL-2) and tumour necrosis factor-alpha (TNF-a)) is mainly instrumental in inducing viral 
clearance (3). Viral persistence on the other hand is associated with T-cell 
hyporesponsiveness, possibly due to exhaustion or paralysis of the immune system due to 
overwhelming antigen presentation (1, 4). Recombinant alpha interferon therapy successfully 
inhibits viral replication in about 30% of the patients with chronic hepatitis B by means of the 
direct antiviral effects of the drug or by inducing a HBV-specific immune response (5). 
Hepatitis A virus (HAV) is transmitted enterally. In highly endemic areas it causes a mild self-
limiting hepatitis among young children. In countries of low endemicity infection occurs at an 
older age. This is associated with a much higher case fatality rate, especially among adults 
over 40 years of age (6). In patients with underlying chronic liver diseases, such as chronic 
hepatitis C, HAV infection can lead to fulminant hepatitis and death (7, 8). 
Data on the impact of HAV infection on chronic HBV are contradictory (7-9). HAV 
superinfection has been reported to have an inhibitory effect on HBV replication during the 
acute phase of HAV. Several anti-viral mechanisms have been postulated to explain the drop 
in HBV protein production: a direct effect of the reduction in target cells following hepatic 
necrosis or viral interference, or an indirect effect due to HAV-induced cytokine production (9-
13). 
During an HAV outbreak among homosexual men in the Rotterdam area we studied a chronic 
hepatitis B patient during an early phase of acute HAV infection in detail. 
Materials and methods 
Viral serology 
Diagnosis of acute HAV infection was based on a highly positive lgM-anti HAV test (IMX, 
Abbott, Chicago, Ill). Co-infections with CMV, EBV, HDV and HIV were excluded by standard 
serology. Acute HCV infection was excluded by PCR. 
HBV DNA was measured by liquid hybridization (Digene II, Murex, UK) and, if negative, by 
PCR (detection limit 400 genome equivalents per ml (geqlml) based on the Eurohep standard). 
HBeAg (IMX, Abbott, Chicago, Ill, USA) and HBsAg (AxSYM HBsAg, Abbott, Chicago, Ill, USA) 
were measured quantitatively and expressed in Paul Ehrlich Units. 
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Measurement of serum cytokine levels 
Sequential serum samples before and during the acute hepatitis episode have been tested for 
levels of circulating IFN-a, IFN-y, IL 10, IL 12, and TN F-a by means of standard sandwich 
ELISA technique. Antibodies for coating and detection, and ELISA reagents were obtained 
from HyCult biotechnology, Uden, The Netherlands (anti-IFN-a), Medgenix Diagnostics, 
Fleurus, Belgium (anti-IFN-y), Pharmingen, San Diego CA, USA (anti-IL 10), R&D Systems, 
Minneapolis MN, USA (anti-IL 12), and CLB, Amsterdam, The Netherlands (TNF-o:). Lower 
detection limits in each assay were: IF N-o:, 50 pglml; IFN-y, 10 pglml; IL 10, 20 pg/ml; IL 12, 80 
pglml; TN F-a, 4 pg/ml. 
Antigens 
Recombinant C-terminal truncated HBcAg particles (146aa) expressed in E.co/i (American 
Research Products, Belmont MA, USA; cat.n.12-3069, batch r-HBcAg-e-CIT-0070) was used 
in lymphocyte stimulation assays. As control antigen, recombinant HCV NS3 protein, also 
expressed in E. coli (American Research Products, cat.n.12-00117, batch 9812ns3) was used. 
Recombinant pre-S,- and pre-S,-containig HBsAg particles, expressed in Chinese hamster 
ovary (CHO) cells, were obtained from Dr. Reinhard Gluck (Swiss Serum and Vaccine Institute 
Berne, Berne, Switzerland). 
In vitro lymphocyte proliferation assays 
Ag-specific lymphocyte proliferative response (LPR) were measured retrospectively culturing 
1 05 thawed peripheral blood mononuclear cells (PBMC) in 4 replicate round-bottom microliter 
wells for 7 days in 0.1 ml of RPMI-1640 supplemented wtth antibiotics and 10% human pooled 
serum in the presence of one of the above described Ag's. Optimal Ag concentration was 
determined as 2 11giml according to titrations performed on PBMC from patients with acute 
hepatitis Band healthy blood donors, either HBsAg-vaccinated or not. [3H]-Thymidine (specific 
activity 5mCi/mmol) was added for the last 20h of culture and the incorporated radioactively 
measured in a ~-scintillation counter. Results were expressed as counts per minute (cpm) and 
the lymphocyte stimulation index (LSI) was calculated as the ratio between median cpm in the 
HBcAg- or HBsAg-containing cultures and median cpm of cultures containing HCV NS3 or no 
added Ag, respectively. The 99th percentile of HBcAg-specific Sl in 10 healthy blood donors 
was 2.29. For practical purposes, specific LPR was scored positive when LSI>3. 
Results 
A 33-year-old homosexual man was known to have been HBeAg-positive since 1995. He was 
a non-responder to a previous 4-month course of alpha interferon in 1996. Lamivudine (150 
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mg once daily) was started in August 1997 and the patient was included in a standardised 
monthly follow-up protocol. The initial drop in HBV DNA ceased after 8 weeks of treatment but 
HBV DNA remained detectable at levels around 108 geq/ml (Fig 1). 
After 24 weeks of lamivudine therapy AlAT, ASAT and bilirubin rose to peak levels of 3061 U/1, 
1764 U/1 and 202 umol/1, respectively. He was jaundiced and complained of malaise, lack of 
appetite and fatigue. There was neither alcohol nor drug abuse. The differential diagnosis 
included lamivudine resistance, drug toxicity, spontaneous clearance of hepatitis B, a post-
lamivudine flare due to non-compliance or super-infection with HAV, HCV or HDV. 
Compliance with his lamivudine medication was demonstrated excluding a lamivudine-
withdrawal flare. He did not use nor had ever used other drugs. No evidence of HIV or HDV 
was found. A YMDD showed wild-type hepatitis B virus. 
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Figure 1 A chronic hepatitis 8 patient infected with HAV during lamivudine treatment. A sudden drop in HBV DNA was 
observed in combination with a hepatitis flare followed by loss of HBeAg. An interferon-gamma peak preceded the rise 
in serum transaminase activity. 
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Extensive virological testing documented an acute HAV superinfection. lgM anti-HAV was 
detectable in serum at the moment serum transaminase activity started to increase. Peak 
serum levels of naturally produced IFN-y, but also IL -10, were measurable just before the rise 
in serum transaminase activity and subsequent drop in HBV DNA levels (Fig 1 ). In these 
samples the levels of IFN-o:, TNF-o: and IL-12 were below the level of detection. The 
proliferative response of PBMC's against the hepatitis B core antigen was already detectable 
before the acute hepatitis, after lamivudine therapy was started and showed no significant 
change after the acute HAV infection (Table 1). No HBsAg-specific response could be 
measured in these samples. 
During the next 2 months HBV DNA dropped further below the level of PCR detection. HBeAg 
and anti-HBe reached borderline values, HBsAg remained detectable at very low levels and 
serum transaminases dropped to normal. 
After seroconversion alpha interferon therapy was started to induce a sustained HBeAg 
seroconversion with detectable anti-HBe antibodies. After 8 weeks of combination therapy 
lamivudine was withdrawn; subsequently HBV DNA became detectable. After 12 weeks of IFN 
monotherapy anti-HBe antibodies were detectable; IFN was given for a total period of 20 
weeks. However, after its withdrawal, HBeAg relapsed. 
Table 1 
HBcAg-specific LPR of the control population versus the LPR overtime Of the acute HAV-infected CHB patient. 
HBc-LSI LSI SE 
Controls: Healthy donors (n 1 0) 1.37 0.14 
AHB (n"'11) 4.21 0.97 
CHB (n=16) 2.14 0.29 
Patient Wk 0 (start lamlvudine) 2.86 
Wk4 3.76 
Wk 48 (after acute HA V) 4.90 
AHB: acute hepatttis B 
SE: standard error 
CHB: chronic hepatitis B 
70 
IFN-Iamivudine combination therapy 
Discussion 
Acute hepatitis A infection has been reported to suppress hepatitis B viral replication in several 
cases (9-13). In acute hepatitis A lysis of infected hepatocy1es is mainly a T -cell-mediated 
cytotoxic mechanism rather than a direct cytopathic effect of the virus (16-18). It has been 
suggested that massive necrosis of infected hepatocytes leads to the decrease in HBV DNA 
(11-13). Hepatitis A caused massive necrosis of infected hepatocytes in our patient, resulting in 
elevated transaminase activity which was followed by clearance of HBV DNA and HBeAg. 
However, it is unlikely that cell necrosis of HBV-infected hepatocytes mediated by HAV-specific 
cytotoxic T lymphocytes eliminates all HBV-infected hepatocytes. 
The contribution of noncytolitic antiviral effects may be of major importance for viral clearance 
in HBV (19). HAV-induced cytokine production is one of the mechanisms which might cause 
HAV-induced suppression of HBV replication (11, 15). lgM anti-HAV positivity coincided with 
the high production of IFN-yfollowed by inhibition of HBV DNA replication. In vitro data suggest 
that IFN-y is the main effective mediator in acute HAV infection. The effects occur at three 
levels: stimulation of HLA antigen expression, direct virus-specific antiviral effects and 
immunomodulatory effects (14). Acute self-limited HBV is probably also mediated by 
predominantly Th1 cytokine production, especially of IFN-y (3). Furthermore, increased IL-12 
levels are associated with HbeAg seroconversion (20). 
In this case HAV-specific IFN-y focused on infected hepatocytes probably caused the drop in 
HBV DNA. An IFN-a peak, as found by Davis et al., could not be confirmed; TN F-a and IL-12 
were also below the level of detection. At the same time the production of IL-10, an immune-
regulating and anti-inflammatory Th2-cytokine, was stimulated probably contributing to the self-
limitation of the response. 
Induction of an HBV-specific response would possibly prevent relapse of the HBV infection. 
Chronic HBV is associated with a weak and ineffective antiviral T -cell response to 
nucleocapside antigens (HBcAg and HBeAg) in contrast to the strong response in acute HBV 
infection (1, 3). In acute exacerbations, spontaneous clearance and response to alpha 
interferon therapy, a re-activated T cell response is measurable, necessary for viral elimination 
(21-23). Restoration of nucleocapside-specific T cell response has been described also during 
lamivudine treatment (4), but the underlying mechanism and its clinical meaning are still 
unclear. Studies in a transgenic mouse model suggest a relevant role for non-cytoly1ic IFN-y 
and TNF-a-mediated suppression of HBV genome expression exerted by HBsAg-specific 
CTLs (24). 
In our patient there was already a pre-existing weak LPR against HBcAg when lamivudine 
therapy was started. As expected no response to the surface antigen was detectable. The LPR 
did not increase after the acute HAV infection, when measured in peripheral blood. This does 
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not exclude an increased response because of the possible compartmentalization of stimulated 
T-cells in the liver (2). However this is not very likely in our patient in view of his relapse after 
withdrawal of therapy. 
HAV-induced production of IFN-y probably induced HBV DNA and HBeAg negativity. However 
this was not combined with stimulation of an HBV-specific T-cell memory which is probably 
necessary to maintain HBe-seroconversion and protection against HBV relapse. In conclusion 
we think that our obse!Vations may contain important implications for specific immunotherapy 
for chronic HBV patients on nucleoside analogue therapy. 
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Abstract 
Background: In chronic HBeAg-positive hepatitis, alpha-interferon (IFN) and lamivudine 
monotherapy lead to HBeAg seroconversion and low-level viral replication in a minority of 
patients. To enhance the HBeAg seroconversion response, we used lamivudine to suppress 
viral replication before starting IFN therapy. 
Methods: In a single centre cohort study 24 HBeAg-positive chronic hepatitis B patients 
received lamivudine monotherapy for a minimum of 16 weeks. IFN therapy was added for at 
least 16 weeks in a dose of 30 MU/week or more. Lamivudine therapy was withdrawn after at 
least 8 weeks of combination therapy. Post-treatment follow-up after stop of interferon therapy 
was 16 weeks. 
Results: A response (loss of HBeAg and HBV DNA from serum) was observed in 4 patients. 
However, this response was sustained in only 2 patients after withdrawal of therapy. Median 
HBV DNA levels decreased during lamivudine monotherapy by 3.2 logs (5-95 percentile 1.4 to 
6.7). IFN therapy further decreased levels of HBV DNA by 1.41ogs (-0.1 to 2.7). Withdrawal of 
lamivudine therapy resulted in an increase in HBV DNA levels by 3.5 logs (0 to 4.4). After 
cessation of IFN, HBV DNA increased further by 0.9 logs (-1.8 to 5.6) until the end of follow-
up. HBV DNA negativity by quantitative PCR (HBVDNA < 1 x 1 03geqlml) was obtained in 6 
out of 24 patients. 
Conclusions: Lamivudine monotherapy followed by IFN-Iamivudine combination therapy 
resulted in strong virus suppression. However a sustained response was obtained in less 
than 10% of these difficult-to-treat patients with the current treatment schedule. No benefit of 
lamivudine pretreatment to a course of IFN therapy could be documented in this cohort of 
patients. 
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Introduction 
Interferon-alpha (IFN) and lamivudine are both licensed for the treatment of chronic hepatitis 
B virus (HBV) infected patients. Loss of HBeAg from serum, either spontaneously or 
following IFN therapy, is correlated with improved survival in chronic HBV (1-4). Therefore 
antiviral therapy in chronic HBV aims at obtaining sustained HBeAg seroconversion. 
IFN therapy for up to 6 months leads to HBeAg seroconversion in 20-40% of patients, 
depending on baseline AL T levels (1, 3, 5). No more than 20% of patients respond with 
HBeAg seroconversion, at one year of lamivudine monotherapy. These low response rates 
emphasise the need for new therapeutic modalities. Combination of interferon with 
lamivudine is one such approach. 
Patients with low baseline HBV DNA and high ALT levels are most likely to respond to IFN 
therapy whereas in lamivudine therapy baseline AL T and HAl score are the most important 
positive predictors of response (3, 6-8). 
Several studies have demonstrated that the overall benefit of lamivudine-IFN combination 
therapy over IFN alone for 16 weeks in chronic HBV is limited (9-11). Efficacy was highest in 
patients with moderately elevated baseline ALT levels (1 0). Recently, it was shown that 
prolonged lamivudine-IFN combination therapy for 6 months significantly increased the 
HBeAg seroconversion rate compared to standard lamivudine monotherapy for 1 year (12). 
In a small-scale study by Serfaty et al sequential administration of lamivudine and IFN in 
previous IFN non-responders induced sustained HBeAg seroconversion in 5 out of 11 
patients (13). 
Whether simultaneous or sequential dosing of IFN and nucleoside analogues should be 
preferred has not been elucidated yet. In this study we added IFN to lamivudine 
monotherapy in chronic HBeAg-positive patients in order to enhance HBeAg seroconversion. 
In addition we extensively studied HBV-DNA kinetics during different treatment phases of 
mono- and combined IFN-Iamivudine therapy. 
PATIENTS AND METHODS 
Patients 
In this single center cohort study eligible patients were HBsAg and HBeAg positive at least 6 
months before start of lamivudine. All patients were above 18 years of age. Patients were 
excluded for the following reasons: other acquired or inherited causes of liver disease (HCV, 
HDV, Wilson's disease, auto-immune disease, hemochromatosis, alcohol or drug abuse); 
significant systemic illness (e.g. cardiovascular or pulmonary dysfunction, HIV, 
transplantation); pregnancy or breast-feeding, antiviral or immunosuppressive treatment in 
previous 6 months; and contra-indications for IFN therapy. 
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Treatment schedule 
Patients received lamivudine monotherapy 150 mg p.o. daily for at least 16 weeks. 
Subsequently, interferon-alpha 2b (lntron A) was added initially at a dose of 10 MU daily for 4 
weeks, followed by a standard dose, 10 MU s.c. thrice weekly. After 8 - 14 weeks of 
combination therapy, lamivudine was withdrawn. IFN monotherapy was continued for more 
than 8 weeks thereafter. IFN therapy was prolonged beyond 16 weeks based on a 
combination of HBeAg levels and HBV DNA levels (5). The follow-up period after 
discontinuation of IFN was 16 weeks. 
Measurements 
Patients were evaluated weekly during high-dose IFN therapy and monthly thereafter. At all 
visits blood was withdrawn for virological markers and serum aminotransferases (ALT, upper 
limit of normal (ULN): 31 IU/1). HBV DNA was measured quantitatively by Hybrid Capture 
plate assay I (Digene, Murex, Abbott UK; detection limit 1.5 x 106 genome equivalents per ml 
(geq/ml) followed by quantitative PCR (PCRQ, Roche Amplicor, Almere, The Netherlands, 
lower detection limit 1 x 103 geq/ml) and if negative by standard PCR (lower detection limit 4 
x 102 geq/ml). All assays were calibrated on the Eurohep standard. HBeAg and anti-HBe 
were tested by AxSYM (Abbott Laboratories, IL, USA). 
Statistics 
All results are presented as median and 5-95 percentiles. The primary end-point was a 
response to therapy defined as loss of HBeAg and HBV DNA negativity (Hybrid Capture 
assay 1). Secondary the HBV DNA levels during the different stages of therapy were 
compared by use of the Wilcoxon signed rank test for paired samples. Each time point was 
compared with that of the previous sample. 
Ethics 
The local medical ethics committee approved this study, all patients gave their written 
informed consent. 
Results 
Twenty-four immunocompetent chronic HBeAg-positive patients were enrolled. Table 1 
summarises the baseline characteristics of the study population. In 4 patients IFN therapy 
was stopped prematurely, primarily for reasons of side effects. The reasons for withdrawal 
were collapse at week 3 of combination therapy in 1 patient, flu-like symptoms at 1.5 weeks 
of combination therapy in 2 patients, and unknown at week 4 of combination therapy in 1 
patient. To assess an optimal analysis of the HBV decay, these 4 patients with early 
discontinuation of combined therapy were excluded from analysis of viral kinetics (per 
protocol analysis). Lamivudine monotherapy was given for a period of 16 to 74 weeks. 
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Combination therapy was given for 8 to 14 weeks. After lamivudine was withdrawn, IFN 
monotherapy was continued for an additional 7 to 28 weeks. 
Viral kinetics 
Median HBV DNA levels after logarithmic transformation and ALT levels during therapy and 
follow up are shown in the upper panel of figure 1, the 5-95 percentiles are added in the 
lower part. 
Phase 1: Lamivudine monotherapy. During lamivudine therapy HBV DNA levels showed a 
median (5-95 percentiles) drop of 3.2 (1.4 to 6.7) logs (p< 0.001). In the initial 4 weeks of 
therapy 66% (2.1 logs) of the reduction was obtained, followed by a gradual decline of 5-9% 
per 4 weeks (0.2-0.3 logs/4 weeks). In the second lamivudine treatment period (beyond week 
4) only 16% of patients (3/19) showed a reduction in HBV DNA levels of more than 0.5 log/4 
weeks. One patient was already HBV DNA negative by PCR at week 4. 
Phase 2: IFN-Iamivudine combination therapy. After addition of high-dose IFN therapy a 1.4 
(-0.1 to 2.7) log reduction was observed (p= 0.002). Eighty-six percent of the total reduction 
in HBV DNA (1.2 logs) was obtained in the initial 4 weeks of combination therapy. In 94% of 
patients (17/18) who were HBV DNA positive by PCR at start of IFN therapy, more than 0,5 
log reduction of HBV DNA was observed during the first 4 weeks of combination therapy. A 
reduction of 2 logs or more was observed in 6/17 patients (35%) during combination therapy. 
Phase 3+4: IFN monotherapy and foil/ow up. Withdrawal of lamivudine was accompanied by 
a significant increase in HBV DNA levels of 3.5 (0 to 4.4) logs (p< 0.001) followed by a 
further increase of 0.9 (-1.8 to 5.6) logs (p< 0.001) after stop of IFN therapy. 
Treatment response 
Results of HBeAg seroconversion, HBV DNA negativity and ALT normalisation after different 
treatment phases are shown in table 2. A response (loss of HBeAg and HBV DNA from 
serum by Hybrid Capture assay) was obtained in 1 patient during lamivudine monotherapy. 
This patient remained HBV DNA positive by PCR before start of IFN. During combination 
therapy another 3 patients responded. A relapse following withdrawal of antiviral therapy was 
observed in 2/4 patients. Thus, in 2/24 (8%) patients a sustained response was observed. 
HBV DNA became negative by PCRQ in 3 patients during lamivudine monotherapy. In 
another 3 patients HBV DNA became undetectable by PCRQ during combination therapy. 
Cessation of therapy was followed by an HBV DNA relapse in 5 out of 6 patients while in 1 
patient HBV DNA levels remained detectable around 2 x1 03 geq/ml. 
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Table 1 
Baseline characteristics expressed as median (5-95 percentiles). 
sex(m/f) 
Age (yrs) 
Race 
previous IFN therapy 
HBV DNA (geq/ml) 
ALT IU/1* 
Cirrhosis (yes/no) 
"'AL Tupper limit of normal31 IU./1 
Table 2 
response 
virological: 
HBeAg negative 
HBV DNA < 1.5 x 106 geq/ml 
HBV DNA< 1 x 103 geq/ml 
biochemical: 
ALT normal 
virological and biochemical: 
start lamivudine start 
IFN 
0 3 (13%) 
1 (4%) 15(63%) 
0 3 (13%) 
8 (33%) 13 (54%) 
0 (0%) 1 (4%) 
84 
12/12 
28 (20-59) 
Caucasian : 12 
Asian :9 
Other : 3 
10 
1.3 X 109 (1.5 X 107 -5.2 X 1010) 
39 (13-198) 
0/24 
stop lamivudine stop 
IFN 
5 (21%) 5(21%) 
21(88%) 5(21%) 
6 (25%) 2(8%) 
14 (58%) 11(46%) 
4 (17%) 2(8%) 
end of 
follow up 
2 (8%) 
3 (13%) 
1 (4%) 
6 (25%) 
2 (8%) 
IFN-Iamivudlne combination therapy 
median reduction 
(JJ.) or increase (11) phase1 phase 2 phase 3 phase 4 
in HBV DNA 
• 
3.2 log~ ., •1.41ogJJ. 
.. .. 
3.5 log ft 11 1111 0.9 log D • 
"E 1.E+12 60 
c- 1.E+11 "E 
-
" 
1.E+10 50 :;) 
"' <( 1.E+09 I-
z ...J 
c 1.E+08 ALT 40 <( 
> 1.E+07 m 
:r: 1.E+06 30 
"' 0 1.E+05 
...J 
1.E+04 20 
1.E+03 HBVDNA 
1.E+02 10 
1.E+01 
1.E+OO 0 
Weeks 0 4 8 12 16-74 0 4 8-28 
after 0 4 8-14 0 4 8 12 16 
start of: Lamivudine 150 mg 1 x dd 
IFN 10 MU daily I tiw 
start start stop stop end of 
lamivudine IFN lamivudine IFN follow up 
HBV 1.2 X 10 2.7x 10 7.2 X 10 3.8 X 10 1.2 X 10 
DNA (3x106-3x1010) (4x102-2x108) (4x102-6x107) (4x102 -1x1010) (4x102-6x101 ~ 
ALT 42 (19-219) 24 (12-51) 24 (14-107) 36 (16-126) 45 (10-634) 
Figure 1 In the upper panel median HBV DNA (geq/ml) and AL T levels (upper limit of normal 31 IU/1) during therapy and follow 
up measured monthly for the per protocol population (n=20) are shown. The 5-95 percentiles calculated at the key 
points during therapy and follow up are added in the lower panel. Lamivudine monotherapy shows a fast initial decline 
of HBV DNA caused by strong inhibition of viral replication followed by a more gradual decline with a wide distribution. 
Addition of IFN causes a further decline of HBV DNA, however after withdrawal of lamivudine viral replication 
increases and after withdrawal of IFN HBV DNA levels returned to baseline levels. 
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Hepatitis flares 
During lamivudine monotherapy an episode of hepatitis flare (AL T > 10 above normal values 
and 3 x baseline level) was observed in 2 patients. After addition of IFN 2 patients 
experienced a hepatitis flare, in one of them the flare was accompanied by a (non-sustained) 
HBeAg seroconversion. In 4 patients withdrawal of IFN therapy was followed by a hepatitis 
flare. These flares occurred 9 to 20 weeks after discontinuation of IFN and 25 to 40 weeks 
after discontinuation of lamivudine. AL T levels increased to levels ranging from 338 to 679 
IU/L. All these patients were retreated with lamivudine monotherapy. 
Discussion 
Pretreatment with lamivudine for 16 weeks followed by 8 weeks of IFN-Iamivudine 
combination and 8 weeks of IFN did not lead to a high rate of sustained HBeAg 
seroconversion. The major effect of lamivudine on drop of HBV DNA levels was in the first 4 
weeks of therapy, thereafter a slow decrease was observed. Adding IFN to lamivudine had 
significant effect on serum levels of HBV DNA and further decreased HBV DNA by 1.2 logs. 
Four out of 24 patients (17%) HBeAg seroconverted during therapy. Sustained HBeAg 
seroconversion was found in only 8%. 
In addition to many immune stimulating effects, the antiviral effects of IFN include blocking of 
entry and uncoating of the virus as well as inhibiting the production of pre-genomic m-RNA; 
these actions probably also lead to the increased blockage of viral replication in patients on 
nucleoside-analogue treatment (14-16). Lamivudine has a potential direct antiviral effect and 
may increase the HBcAg and HBeAg mediated T-cell response suggesting pre-treatment 
may be beneficial (17). 
The benefit of lamivudine-IFN combination therapy in chronic HBV has not yet been 
elucidated, as has the optimal duration and treatment schedule. The overall benefit of 
simultaneous dosing of lamivudine and IFN for 16 weeks has been debated for both IFN 
naive and IFN non-responders (9-11). Subgroup analysis showed most benefit in patients 
with moderately elevated ALT. A prolonged course of lamivudine-IFN combination therapy 
showed to enhance the HBeAg seroconversion rate (12). In that study group, harbouring 
patients with relatively high baseline transaminase values, HBeAg seroconversion was 15% 
for those treated with lamivudine and 33% for those treated with lamivudine-IFN combination. 
Promising results were obtained in a pilot study including 14 previous IFN non-responders, 
11 HBeAg positive patients, using an add-on therapy with IFN following lamivudine 
monotherapy (13). Lamivudine monotherapy for 24 weeks was followed by 4 weeks of 
lamivudine-IFN combination therapy, after which lamivudine was withdrawn and IFN 
continued for another 24 weeks. A sustained HBeAg-response was observed in nearly 50% 
(5/11) of patients. 
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The limited sustained response rate in this study is related to both low initial response as to 
high relapse rates. Low initial response is primarily related to low baseline AL T and high HBV 
DNA levels in our population. Baseline characteristics, especially AL T, are important 
predictors of a sustained response (7, 10). ALT levels below 2 times ULN are associated with 
a decreased response rate during mono -or combination therapy with lamivudine and IFN (7, 
10). The relatively high relapse rate in our study could also be dependent of high pre-
treatment HBV DNA and low pre-treatment ALT levels (18). These negative response-
predictive factors are in particular important following lamivudine-induced HBeAg 
seroconversion. Early withdrawal of lamivudine, a few weeks following HBeAg 
seroconversion, may be another factor that contributed to high relapse rate in this study. The 
period of continuation of lamivudine after HBeAg seroconversion is correlated with the post-
treatment relapse rate. Unlike IFN-induced HBeAg seroconversion, which is stable in over 
85% of patients, there is disagreement about the durability of lamivudine-induced HBeAg 
seroconversion (19). By some it is claimed to be as durable as IFN induced seroconversion, 
while others reported a relapse rate in up to 49% of patients (19-22). 
In conclusion IFN had a significant additional effect to lamivudine monotherapy on inhibition 
of viral replication. This favourable kinetic profile did not result in high sustained HBeAg 
seroconversion rates. Sequential withdrawal of therapies was followed by a relapse of viral 
activity in the majority of patients. Whether simultaneous dosing of both drugs will lead to a 
better virus suppression and whether prolonged therapy might lower relapse rates has to be 
investigated in future studies. 
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Abstract 
Background: Whether the combination of lamivudine and alpha-interferon (IFN) increases the 
effectivity of antiviral therapy in chronic hepatitis B is unclear. To determine a potentially 
increased antiviral effect of combination therapy, we studied the viral kinetics of hepatitis B 
during the first 16 weeks of lamivudine monotherapy, IFN monotherapy and lamivudine-IFN 
combination therapy. 
Patients and Methods: Forty-nine patients (40 males, 9 females), treated in 3 randomized 
trials, were included. Twenty-one patients were treated with lamivudine monotherapy (150-
600 mg daily), twenty received IFN monotherapy (10 MU tiw) and eight patients received 
lamivudine (1 00 mg daily) combined with IFN (1 0 MU tiw). Sequential sera, taken at week 0, 
1, 2, 3, 4, 8, 12, and 16 of therapy, were tested for HBV DNA by Hybrid Capture assay 
followed by quantitative and qualitative PCR (detection limit 400 geq/ml). The decay of viral 
load was described by a piecewise linear regression analysis (model 1), and in addition, by 
non-linear regression analysis according to Neumann (model 2). Further analysis was 
performed taking into account variations in baseline factors, especially serum ALT. 
Results: The three treatment groups were comparable regarding baseline characteristics, 
with the exception of AL T being significantly higher in the IFN treated patients. Lamivudine 
containing therapies showed the largest decline in the first phase of the viral decay curve, 
whereas the second phase appeared mainly infiuenced by IFN containing therapies. After 
correction for baseline AL T levels, the second phase of viral decline was significantly more 
rapid for combination therapy compared to IFN and lamivudine monotherapy, which were 
similar. Nearly all patients receiving combination therapy are theoretically expected to reach 
viral negativity compared to 55-65% for monotherapy with either drug. The estimated median 
time needed to obtain viral elimination from serum was 39 weeks for combination therapy, 
but 84 and 89 weeks for IFN and lamivudine monotherapy respectively. 
Conclusions: In comparison with monotherapy, combination of interferon and lamivudine 
reduces the estimated time to viral negativity, and increases the percentage of patients 
reaching that endpoint. Prolongation of combination therapy to 1 year might enhance viral 
clearance in patients chronically infected with the hepatitis B virus. 
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Introduction 
The limited efficacy of standard treatment courses with either alpha-interferon (IFN) or 
lamivudine, and the time-dependent emergence of viral resistance during prolonged 
lamivudine monotherapy emphasize the need for new approaches for therapy in chronic 
hepatitis B. Combination therapy of interferon with lamivudine is one such approach. 
Two large studies on combination therapy in HBV have been performed, both with HBeAg 
seroconversion and HBV DNA negativity (by conventional hybridization assay) as an end-
point (1-2). For treatment-naive patients an enhanced HBeAg seroconversion rate was 
reported for combination therapy in comparison to IFN or lamivudine monotherapy, 
particularly in patients with elevated pre-treatment AL T; overall the additional benefit was 
limited (1 ). For previously IFN treated non-responder patients no benefit of combination 
therapy over lamivudine monotherapy could be demonstrated (2). 
Combination of both drugs in the two large studies was for 16 weeks. However, the decay 
curve of hepatitis B virus during combination therapy points to the need for longer therapy 
than 16 weeks to reach virus elimination (3). The curve during therapy with nucleoside 
analogues exhibits a bi-phasic decline (4), as in hepatitis C (5). The initial fast phase 
represents the clearance of free viral particles from serum, its magnitude and duration are 
believed to relate to the effectiveness of antiviral therapy in blocking viral production; the 
slower second phase is thought to represent the immune-mediated clearance of infected 
hepatocytes. To further investigate the antiviral effect of combination therapy versus 
monotherapy, we measured HBV DNA in stored serum samples of patients who completed 
lamivudine therapy, IFN monotherapy, or combination therapy, analyzed the (biphasic) 
decline and calculated both the effectiveness of therapy in inhibiting viral production as well 
as the clearance of cells infected with hepatitis B virus. 
Patients and Methods 
Patients 
Forty-nine compensated chronic hepatitis B patients who participated in 3 randomized trials 
were included. 
Group A consisted of 21 patients participating in a viral kinetics study of lamivudine 
monotherapy (6). All patients received lamivudine at least 150 mg daily for more than 16 
weeks. Eleven patients were treated with 600 mg of lamivudine daily during the first 4 weeks; 
since a dose higher than 150 mg did not affect the viral kinetics, patients receiving either 150 
mg or 600 mg of lamivudine were considered as one group (6). 
Group B consisted of 20 patients that were all treated with IFN 10 MU tiw during the first 16 
weeks of a randomized controlled trial (7). In 96 of 162 patients stored serum on 5 specific 
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time points (vide infra) was available; out of these 96, 20 patients were randomly selected by 
a computer generated program. 
Group C were all 8 patients from Rotterdam and Birmingham who received IFN 10 MU tiw in 
combination with lamivudine 1 00 mg daily for 16 weeks in a randomized trial on lamivudine-
IFN combination therapy in previous IFN non-responders (8). 
In addition, we analyzed HBV DNA levels in a new Rotterdam cohort of 5 consecutive 
HBeAg-positive patients who were treated with long-term combination therapy of lamivudine 
(150 mg daily) and IFN (10 MU tiw) after closure of entry to the controlled trial. 
Virologic measurements 
Sequential serum samples for HBV DNA measurements were taken before start of therapy, 
at week 1, 2, 3, 4, 8, 12 and 16. For IFN monotherapy samples at week 1 and 3 were not 
available. During combination therapy an additional sample was taken at week 6. HBV DNA 
was measured quantitatively by Digene Hybrid Capture II plate assay (detection limit 2x1 05 
copieslml) and quantitative PCR (Roche Amplicor, Almere, The Netherlands, detection limit 
103 copieslml) and if negative by qualitative PCR (lower detection limit 400 copieslml). All 3 
assays were calibrated on the Eurohep standard and interchangeable (9). 
Mathematic modeling and statistics 
Viral kinetics were fitted in 2 ways. In the first method we calculated and compared viral 
kinetics by piecewise linear regression (model 1). In the second method we used non-linear 
regression analysis (model 2) which has previously been described by Neumann et al. (5) for 
hepatitis C and modified by Tsiang (4) for hepatitis B. 
Model 1: piecewise linear regression The piecewise linear regression model with one 
breakpoint at week tbreak is given by: 
r V0 +b1t 
v (t)= 
V= log transformed viral load (HBV DNA) 
V0 = initial viral load (log transformed) 
b1= slope of first phase 
b2= slope of second phase 
t= treatment time (week) 
fort< tbreak 
for t> tbreak 
The piecewise linear regression model was fitted in SAS 8.00 with PROC MIXED with 
random intercept V0 and slopes of viral decline b1 and b, per individual, using an 
unstructered covariance matrix for the random effects. The break point of the lines tbreak was 
fitted seperately for each therapy using non-linear regression analysis (macro NLINMIX in 
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SAS 8.00) (including random effects per individual): for LAM: t,.,,, =week 1; for IFN + LAM: 
tbreak. =week 1; and for IFN: no break point was found because measurements within the first 
2 weeks were not available. Based on the assumption that IFN therapy, as in HCV infection 
(5), induces a biphasic HBV DNA decay the theoretical breakpoint was set at week 1: tb"'' = 
week 1. 
In addition we used model 1 in adaptive versions to correct for differences in baseline ALT. A 
correction factor was added to each parameter V0 , b1, b2 . Each parameter is written as a 
sum of two factors. The first factor represents the level of the reference (ALT<2x ULN), the 
second reflects the difference between the reference and the corrected value (AL T 2-5x 
ULN orAL T > 5xULN). For example: V(t) = 0/o +Vo om•ct,,)+(b1+ b'""'ct,,)t 
Model 2: non-linear regression The non-linear regression model based on the work of 
Neumann (5) and Tsiang (4) yields a biphasic curve. Mathematically the model is as follows: 
V (t)= Vo+ log(Aexp(-l.,t)+ (1-A)exp(-l.,t)} 
where V= log transformed viral load (HBV DNA), Vo = initial viral load (log transformed), A is 
correlated to the duration of the first phase, /.1 the slope of the first phase and 1.2 the slope 
of the second phase. These parameters have been transformed to biological parameters: c 
(clearance rate of free virus from serum), £ (effectiveness of blocking virion production), 11 
(efficacy of blocking the de novo infection of uninfected cells) and o (death rate of infected 
cells) (5): 
1.,,,=%{(c+o) ±[(c-o)'+ 4(1-£)(1-ll)co] y,l 
Model 2 was fitted with mixed-effects theory using the macro NLINMIX in SAS 8.00, with two 
exponential curves. With this technique the entire data set can be analyzed and therapy 
specific dynamic parameters can be estimated. The individual deviation from the therapy 
specific curves are estimated by including random effects for each subject specific parameter 
set. 
The results of the mathematical calculations for each therapy group were compared using 
the Log likelihood test, the level of significance was set to p< 0.05. 
Time to viral negativitv Assuming that the slope of the viral decline of the second phase can 
be extrapolated, the viral load at timet beyond 16 weeks can be predicted using model 1 or 
model 2. Furthermore the probability of the viral load V(t) reaching some detection limit D at 
timet: Prob('/(t)<D), can be calculated: under the fitted model 1 V(t) is described by a normal 
distribution mean given by model 1 and with standard deviation SD('/(t)). The standard 
deviation of the viral load at timet: SD('/(t)) can be estimated by the fitted covariance matrix 
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of the random effects (model 1 is here extended with a block diagonal covariance matrix, 
existing of blocks corresponding to the therapies). It then follows that 
Prob (V(t)<D)= ${(D-V(t))/ SD(V(t))}, 
where$ is the standard normal cumulative density function. 
Other statistics For comparison of baseline nominal variables the x2 were used, continuous 
variables were compared with the one-way Anova or Kruskai-Wallis test. 
Results 
The baseline demographics of the 3 therapy groups are shown in table 1. Significant 
differences are observed for age (lamivudine), previous antiviral therapy (interferon), and 
baseline ALT (interferon). In view of the documented effect of serum ALT on both viral 
kinetics (6) and outcome of antiviral therapy (1 ), we repeated the comparison of therapy 
groups after correction for baseline ALT. 
Table 1 
Baseline dlaracteristics expressed as median value (s'h- 951h percentiles). 
LAM IFN 
n 21 20 
Age (yrs) 29 (18- 53) 47(31-61) 
Sex(m!f) 18/3 13/7 
Previous A \IT' 
IFN 9 0 
Race 
Caucasian 11 17 
Asian 7 2 
Other 3 1 
AL T (IU/1)11 62 (18- 596) 103 {27- 332) 
<2 x ULN 10 4 
2-5 x ULN 9 11 
>5 x ULN 2 5 
HBV DNA (geq/ml)• 1.2 X 109 1.4x109 
{3.1 x107-1.3x1010) {1.5 x107-2.5 x1010) 
• A VT antiviral therapy 
•t upper limit of normal (ULN): 30 IU/1 
• measured by Digene Hybrid Capture assay (Digene, Diagnostics) 
LAM+IFN 
8 
43 (34- 68) 
810 
a 
5 
3 
0 
48 (25 -108) 
5 
3 
0 
1.7 X 109 
(7.4 x107-7.1 x109) 
0.00 
0.08 
0.00 
0.17 
0.01 
0.62 
Kinetic results per therapy group: Figure 1 illustrates the average decline of the HBV DNA 
values per therapy group fitted by both models. A bi-phasic decline was observed during 
lamivudine monotherapy and combination therapy. In patients treated with IFN monotherapy 
a breakpoint in the viral decay curve could not be calculated (no HBV DNA measurements in 
the first 2 weeks) and a theoretical breakpoint was set at week 1. Both models (piecewise 
linear regression analysis and non-linear regression analysis) showed a similar fit according 
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to the log likelihood ratio and Akaike's information criteria (AI C) (table 2). Independently of 
the model, viral decline during the first phase is largest in lamivudine-containing therapies 
whereas viral decline during the second phase is more pronounced during IFN therapy with 
or without lamivudine. 
Viral kinetic parameters (by piecewise linear regression analysis and non-linear regression 
analysis) are shown in table 2. Viral kinetics of the first rapid phase shows a 2.6-2.71og drop 
of HBV DNA during the first week of combination therapy. This viral decline was significantly 
faster compared to the 1.5-1.8 log of lamivudine monotherapy (ps;0.001) and 0.4-0.5 log of 
IFN monotherapy (p<0.0001). The initial fast drop was followed by a much slower second 
phase. However, the viral decline remained significantly faster during combination therapy 
(0.17-0.18 log/week) compared to lamivudine monotherapy (0.08-0.10 log/week) (p<0.045). 
The viral decline of second phase during IFN monotherapy (0.11-0.131og/week, p>0.10) did 
not significantly differ from combination therapy. 
The results for combination therapy in patients derived from randomized controlled trials 
could be confirmed in a subsequent cohort of 5 consecutive patients with chronic HBeAg 
positive hepatitis B who were treated after closure of entry to the controlled trials. The viral 
decline pattern was similar to the 8 patients included in the study (median decline of HBV 
DNA 2.82 log/1st week in the first phase and 0.16 log/week in the second phase (piecewise 
linear regression)). 
The results of the viral dynamics analysis by non-linear regression for the different 
therapeutic regimens are given in table 3. The effectiveness of a drug in blocking viral 
replication (<), calculated from the viral clearance observed during the first phase, was 99% 
for lamivudine, 99.8% for combination therapy and 83% for IFN; the latter figure is only a 
rough estimate of the true value due to the absence of first week serum samples. The death 
rate of the infected cells (8), calculated from the viral decay curve during the second phase, 
was higher with combination therapy compared to lamivudine monotherapy (half-life of the 
infected cell 12.7 versus 26.7 days for combination and lamivudine therapy, respectively). 
The half-life of infected cells with IFN monotherapy (16.1 days), did not significantly differ 
from combination therapy. 
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Piecewise Linear Regression Non-linear Regression 
E 
-0" Q) 
9 
weeks after start of therapy 
Figure 1 HBV DNA decline curves (population median curve and 75 percentile), calculated by piecewise linear regression and 
by non-linear regression. Note the marked decrease of HBV DNA of LAM (with or without IFN) in phase 1, and the 
stronger effect of IFN (with or without LAM) on phase 2. The range of HBV DNA values (75 percentiles) with 
combination therapy is smaller than with monotherapy with LAM or IFN, reflecting a more uniform pattern of response. 
These results appear to be independent of the regression analysis used. 
Table 2 
Viral kinetics: decrease in HBV DNA over time calculated by 2 methods. 
decrease in HBV DNA (log/Week) 
model Time period LAM (X 95% Cl) IFN (X 95% Cl) 
Wk0-1 1.85 (1.58-2.12) 0.48 (0.18-0.78) 
lfVk 1-16 0.10 (0.05-0.14)tt 0.11 (0.07-0.16} 
2 Phase 1 1.53 (1.20-1.86}t 0.41 (0.00-0.87)t 
Phase 2 0.08 (0.04-0.12)tt 0.13 (0.05-0.15) 
Results are given as means and 95% confidence intervals. 
Modell: piecewise linear regression. Model fitting information: log likelihood= 1254.0 (AIC=-634.0). 
Model 2: non-linear regression. Model fitting information: log likelihood = 1263.4 (AIC=-638. 7). 
tsignlficantly different from LAM+ IFN: p<0.001 
ttsignificantly different from LAM+ IFN: p<0.05 
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LAM+ IFN (x 95% Cl} 
2.71 (2.28-3.14) 
0.18 (0.11-0.24) 
2.65 (1.96-3.28) 
0.17 (0.10-0.23} 
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Time to viral negativity by therapy group Assuming that the slope of the viral decline of the 
second phase can be extrapolated, the time to viral negativity was estimated using the 
results of model 2 (table 3). The mean estimated time for complete elimination of all viral 
particles from serum (till1 copy/ml) is 274 days (39 weeks) for combination therapy, which is 
significantly shorter than that for monotherapy of either drug (Table 3). The probability to 
reach the detection limit of currently available HBV DNA assays over time using the results of 
model 1 are shown in figure 2. The combination of lamivudine and IFN markedly decreased 
the time necessary to reach HBV DNA negativity by either liquid hybridization or PCR 
(detection limit 400 geq/ml). Furthermore this figure shows that by combining both drugs, 
HBV DNA negativity by PCR is theoretically obtainable in nearly all patients, whereas for 
monotherapies the curve tends to level off around 70% of patients. 
Kinetic results corrected for baseline AL T: Independently of the therapy given, there was an 
overall significant effect of baseline AL T on the decline rate of HBV DNA of the second 
phase (Po~~~~= 0.004): a higher AL Twas associated with a faster decline in HBV DNA. After 
correction for baseline ALT the decline of HBV DNA during the first phase remained 
significantly faster for combination therapy compared to either lamivudine or IFN 
monotherapy. For the second phase the difference in decline of HBV DNA between 
combination therapy and lamivudine was 0.10 log/week (95% C.l. 0.03-0.17, p=0.008) and 
between combination therapy and interferon 0.11 log/week (95% C.l. 0.03-0.19, p=0.006). In 
contrast; the second phase of lamivudine and IFN therapy showed comparable decline: the 
overall difference was 0.01 log/week week (95% C.l. -0.04-0.07) after correction for baseline 
ALT (p=0.73). 
Discussion 
In this study combination therapy of lamivudine and IFN results in a significant more rapid 
decline of hepatitis B virus, both in the initial and in the second phase. According to 
theoretical extrapolation of the viral kinetic data the mean duration of therapy necessary to 
obtain viral clearance from serum was 39 weeks, whereas it is more than 85 weeks with 
monotherapy of IFN or lamivudine (table 3). Based on current data, nearly 100% of patients 
will reach the detection limit of the HBV DNA-PCR assay within 52 weeks, this result will 
occur in less than 50-60% of patients receiving monotherapy for this period. 
In chronic HCV, viral clearance from serum is the generally accepted key outcome measure, 
in HBV viral negativity by PCR is not an endpoint of antiviral therapy. The two endpoints 
proposed at a recent NIH workshop (10) are HBV DNA less than 105 copies/ml refiecting 
inactive chronic hepatitis B, and HBsAg-negativity refiecting a sustained response and - in 
most instances- cure. 
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Viral dynamics: dynamic parameters derived from the non-linear regression analysis for the 3 different therapy groups, LAM, IFN and LAM+IFN. 
phase 1 phase 2 
Clearance of serum virus Inhibition of virus production Loss of Infected cells 
Clearance Virus half-life Efficacy(%) Death rate Infected cell half-
rate (1/day) (days) (1/day) life (days) 
c T~ £ 8 T Y.,2 
LAM 0.50 1.4 99.0 0.025 26.7 
(n.a.) (n.a.) (98.9-99.1) (0.0004-0.062) (11.2-149.8) 
IFN I 0.13 5.6 82.7 0.043 16.1 
(n.a.) (n.a.) (68.3-97.9) (0.0004-0.1 07) (6.5-179.7) 
LAM+IFN I 0.86 0.8 99.8 0.054 12.7 
(n.a.) (n.a.) (99.7-99.9) (0.031-0.083) (8.4-22.6) 
Estimated time for viral 
negativity 
(days) 
620 
(190-3387) 
594 
(192-7549) 
274 
(183-321) 
Results are expressed as the mean population averages with the 5th- 95th percentile of individual patients between brackets. Note the small variation in 8 for LAM+ IFN combination therapy 
n.a: not applicable since the random effect for C was fixed by necessity in the modeL 
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Figure 2 The probability to reach the detection limit of currently ava!fable HBV DNA assays as well as complete elimination of virus from serum (1 copyfml), by therapy group over time using the 
results of model 1. These results, based on extrapolation of the week 0-16 data, suggest that 1 year of combination therapy produces maximal virus suppression as well as a clinically 
significant improvement over monotherapy. 
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Patients reaching a HBsAg negative state also are HBV DNA-PCR negative, but HBV DNA-
PCR negativity does not equal HBsAg negativity. In HBV, inactivechronic hepatitis can be the 
result of treatment in maximally 40% of patients on IFN therapy (11, 12), whereas loss of 
HBsAg occurs in about 10% over a period of 5 years. We believe that the percentages of 
responses will increase when virus clearance from serum will also become a goal of 
treatment; we are aware that this concept needs further proof. 
Data on viral kinetics and dynamics are often based on a limited number of patients (4, 5, 13-
15). Also in this study the confidence in the results and conclusions is hampered by the small 
number of patients, especially in the combination therapy group. Selection bias was 
minimized by either randomly choosing patients from a large group (IFN), or including all 
patients treated in the trial (lamivudine) or all patients from 2 centers (combination therapy). 
This approach, however, resulted in significant differences for various baseline factors; we 
corrected our model calculations successfully for the differences in baseline ALT, the only 
different factor of proven significance. Although the data for combination therapy were only 
based on 8 patients, we believe the data are valid since the pattern of response to 
combination therapy was rather uniform (small range for e, 8 and estimated time for viral 
elimination, table 3) in contrast to the wide range of responses seen with IFN or lamivudine 
monotherapy. We had the choice to enlarge the combination group to 13 patients or to test 
the model in a new cohort of 5 patients. We attributed the largest confidence to confirmation 
of our findings in another group; in fact, the results for the 8 study patients were similar to 
those of the new cohort of 5 consecutive patients. Despite the small number of patients 
studied and the differences in baseline characteristics, we think the results of our analysis 
can be used as the best available rough estimates; however, further research is warranted to 
determine more precise values of viral kinetics in chronic hepatitis B. 
The major conclusions about the kinetics of HBV DNA decay were independent of the model 
used. Dynamic parameters can only be calculated with the non-linear regression analysis (5). 
It has to be taken into account this model is designed for a 4-week treatment period in HCV 
patients during IFN. We used the model generally accepted for assessment of 4-week IFN 
treatment in HCV for an extended treatment period of 16 weeks in HBV patients on 
lamivudine, IFN or combination therapy. For the original model, it was assumed that the 
major effect of IFN is blocking viral replication rather than blocking de novo infection (5). We 
think this assumptions is also true for IFN and lamivudine in hepatitis B, although blocking de 
novo infection may play a role in IFN containing therapies. Further developments in 
mathematical modeling and antiviral therapy however are necessary before the biological 
effects of antiviral therapy can be described with confidence. 
We were hampered by the lack of "week one" samples in the IFN treated group. By 
piecewise linear regression analysis we could not calculate a breakpoint because of the 
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paucity of early data points. We therefore choose to set the breakpoint at week one, the 
same as for the other therapies. Repeating the analysis without a breakpoint for IFN gave 
similar results (results not shown), and hence did not infiuence the conclusions. This and 
other studies (4) using only first samples at 1 week, suggest a transition of the first to second 
phase within the first week in HBV. Daily sampling during the first week of therapy will result 
in a higher calculated value of the clearance of the free virus from serum, a decrease of the 
corresponding half life of the virus, and a shorter duration of the first phase (6). 
This study suggests that combination therapy increases the slope of the viral decline from 
serum, presumably by causing greater inhibition of virus production. Previous studies 
showed that higher dosing of antiviral therapy only increased the duration of the first phase 
but did not affect the slope of the viral decline from blood (5). The increased efficacy of 
combination therapy of famciclovir and lamivudine was also caused by the prolongation of 
the first phase, combination therapy of these 2 nucleoside analogues did not influence the 
half life of free virus (15). Future studies, including frequent early sampling, have to elucidate 
whether the increased effectiveness of lamivudine-IFN combination therapy is due to an 
increased viral decline curve, a prolonged first phase or a combination of both effects. 
Baseline AL T has been identified as a key baseline factor influencing the HBeAg 
seroconversion rate (1, 11, 16). The importance of pre-treatment ALT as a marker of host 
immune reactivity also emerged from this study, since a significant positive effect of ALT on 
the slope of viral decay was observed, independently of the therapy given. It has been shown 
previously in HCV that the slope of the second phase is positively correlated to baseline AL T 
levels, refiecting pre-treatment cellular immune responsiveness (5). This supports the 
hypothesis that the second slope is dependent on the immune-mediated death rate of 
infected cells (3), next to the blocking effect of drug on viral replication. 
Therefore it is of major importance to correct for baseline AL T levels when comparing the 
effects of different treatments. After correction for baseline AL T the second phase of the viral 
decay curve became comparable for the two monotherapies, whereas combination therapy 
was associated with a significantly faster viral decline in both phases compared to 
monotherapy. To obtain sustained viral clearance, the death rate of the infected cells is 
probably the most important factor. The combination of lamivudine and FN reduced the half 
life of the infected cells compared to lamivudine monotherapy. 
We used the kinetics of the second slope of viral decay to predict the estimated time to 
negativity, showing a strong reduction in time necessary to obtain viral negativity with 
combination therapy. Since biological mechanisms may change over lime, the extrapolation 
of data for prediction of the duration of therapy has to be interpreted with caution. 
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Nevertheless, this study shows that the duration of combination therapy in HBV patients has 
to be prolonged to at least 26-46 weeks, assuming that complete virus suppression is a 
prerequisite for improved results of antiviral therapy in HBV. 
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Abstract 
Background & Aims: Interferon (IFN) induced HBeAg-seroconversion is durable in 80-90% of 
chronic hepatitis B patients. Preliminary reports on the durability of HBeAg seroconversion 
following lamivudine are contradictory. We investigated the durability of response following 
IFN, lamivudine or IFN-Iamivudine combination therapy in a meta-analysis of individual 
patient data. 
Patients and Methods: Twenty-four centers included in total 130 patients with an HBeAg 
seroconversion (HBeAg negative, anti-HBe positive) at the end of antiviral therapy: 59 with 
lamivudine, 49 with interferon, and 22 with combination therapy. Relapse was defined as 
confirmed reappearance of HBeAg. 
Results: The 3-year cumulative HBeAg relapse rate by the Kaplan-Meier method was 54% 
for lamivudine, 32% for IFN and 23% for combination therapy (p=0.01 ). Cox regression 
analysis identified pre-treatment HBV DNA, AL T, gender and therapy as independent 
predictive factors of post-treatment relapse; Asian race, previous therapy, center and type of 
study were not predictive of relapse. The relative HBeAg relapse risk of lamivudine 
compared to IFN therapy was 4.6 and that of combination therapy to IFN therapy 0.7 
(Poveraii=0.01). 
Conclusions: The durability of HBeAg seroconversion following lamivudine treatment was 
significantly lower than that following IFN or IFN-Iamivudine combination therapy. The risk of 
relapse after HBeAg seroconversion was also related to pre-treatment levels of serum AL T 
and HBV DNA, but independent of Asian race. 
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Introduction 
Loss of HBeAg, either spontaneously or following alpha-interferon (IFN) therapy, significantly 
improves the clinical outcome and survival in chronic hepatitis B virus (HBV) patients (1-3). 
Therefore HBeAg loss with seroconversion to antiHBe has remained a major end-point of 
antiviral therapy in chronic HBV infection. 
Monotherapy of 16-26 weeks of IFN is associated with loss of serum HBeAg in 20 to 40% of 
patients, depending on baseline AL T levels (4). Several long-term follow-up studies have been 
carried out in IFN responders showing that IFN induced HBeAg seroconversion is sustained in 
around 80-90% of patients (1-2, 5-10). IFN responders are more likely to clear HBsAg (23-
86%) from serum than spontaneous seroconverters during a median follow up of 3.8 to 9 years 
(1-2, 5-6, 10). 
HBeAg-seroconversion is observed in 15-30% of patients at 1-2 years of lamivudine therapy 
(11-14). The clinical implication of lamivudine induced HBeAg seroconversion is suggested to 
be comparable to that of seroconversion following IFN therapy (12, 15-16). A relapse of HBeAg 
was observed in 19% (8/42) of patients with a response after lamivudine (16). On the contrary, 
a single-center cohort study showed a considerable higher percentage of relapse, increasing to 
50% (16/32) at 2 years (17). 
Combination therapy of 16-26 weeks results in HBeAg seroconversion in 29% of treatment-
naive patients, and in 12% of previous IFN non-responders (13, 18). Reports on durability of 
seroconversion after IFN-Iamivudine combination therapy reflect only the first 16 weeks after 
therapy; similar relapse rates are reported for responders after combination therapy (22%) 
compared to lamivudine (23%) and IFN (25%) (19). 
Large comparative long-term post-treatment studies are lacking. To investigate the post-
treatment durability of HBeAg seroconversion following lamivudine, IFN monotherapy or IFN-
Iamivudine combination therapy, we performed a multicenter meta-analysis of individual 
patient data. Since such a study does not include randomization•, we have taken strict 
precautions to minimize differences in outcome due to age, sex, race, previous therapy, 
baseline AL T and HBVDNA, and treatment center. Multivariate analysis stratified for center 
was performed to obtain the currently best estimate of the durability of HBeAg 
seroconversion following the 3 therapies; in addition factors predictive of relapse were 
identified. 
• it is impossible to do a randomized study on the posttreatment durability of HBeAg 
seroconversion since the inteiVention is prior to reaching the inclusion criterium. 
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Patients and Methods 
Long-term follow-up data of chronic HBV patients with a HBeAg seroconversion after antiviral 
therapy were collected. We contacted 53 centers that had patients with HBeAg 
seroconversion in randomized controlled trials, in which we participated ourselves (13, 18, 
2a-21). In addition 5 centers submitted data from patients treated in cohort studies between 
1998-2aaa. Patients who were HBV DNA and HBeAg posttive before start of antiviral therapy 
were eligible if they seroconverted after receiving lamivudine in a dose of at least 1 aa mg 
daily for 24 weeks or more, IFN monotherapy 3a million units per week for at least 16 weeks 
or IFN-Iamivudine combination therapy for at least 16 weeks. 
HBeAg seroconversion was defined as loss of HBeAg, appearance of anti-HBe and HBV 
DNA negativity (hybridization methodology), on 2 occasions at least 1 month apart, at the 
end of lamivudine monotherapy, or within 12 months of initiation of IFN therapy in case of 
IFN mono or combination therapy (9). Patients were excluded if at baseline there were co-
infections (HCV, HDV or HIV), signs of decompensated cirrhosis (defined as jaundice, 
variceal bleeding, ascites or encephalopathy) or other causes of liver disease . 
Virologic and biochemical measurements 
We collected follow-up data on HBeAg, anti-HBe, HBVDNA, HBsAg and ALT, 1 month 
before the end of therapy, at the end of therapy, 3, 6 and 12 months after the end of therapy 
and yearly thereafter. 
Serum HBeAg, anti-HBe and HBsAg were measured using routine commercially available 
immunoassays IMx (Abbott, Chicago, IL), Kodak Amerlite (Kodak Clinical & Diagnostics, 
Amersham, UK) or DiaSorin (Verceln, Italy). Depending on the center and date of 
measurement, serum HBV DNA was measured using the solution hybridization assay by 
Abbott (Chicago, Ill, detection limit 2x1 a' geq/ml), bDNA-assay (Chiron, Emeryville, CA, limit 
of detection 7x1a5 geq/ml) or a hybrid capture tube assay (Digene, Murex, UK, detection limit 
1 ,5x1 a' geq/ml); all HBV DNA results were converted to Eurohep genome equivalents (22). 
ALT (IU/1) was expressed as times the upper limit of normal (ULN). 
Definition of relapse 
Relapse was defined as reappearance of HBeAg in serum, confirmed by HBV DNA posttivity 
in the same sample or by HBeAg positivity in a consecutive sample. Relapse of HBV DNA 
was defined as reappearance of HBV DNA in serum above the cut-off for the method 
employed. 
Statistics 
Results are presented as mean ±standard deviation. The cumulative relapse rate for the total 
study population was calculated by the Kaplan-Meier method with the log-rank test for 
statistical comparison between groups. Multivariate analysis was performed by Cox 
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regression analysis with the likelihood ratio test for statistical significance. To account for a 
possible center effect the Cox regression was stratified by center; centers with less than 4 
patients were clustered in one stratum. Furthermore, interactions between therapy, Asian 
race, baseline ALT-Ievel, baseline HBV DNA, gender and previous therapy were 
investigated. Sensitivity analysis was performed excluding one center at a time. The level of 
significance was set to p<O.OS. 
To determine whether the duration of lamivudine therapy influences relapse rates, a Cox 
regression analysis stratified for center was performed on the subset of patients on 
lamivudine (n=59) with 3 categories (24-48 wks, 48-72 wks, and more than 72 wks). 
Results 
Worldwide 24 centers from 14 countries included 130 patients with chronic hepatitis B who 
had responded to antiviral therapy with HBeAg seroconversion (in 1 case no data on anti-
HBe were available). Baseline characteristics are presented in table 1. Fifiy-nine patients had 
received lamivudine, 49 IFN and 22 combination therapy; seventy-one patients received the 
treatment as participant in an international RCT. Follow-up till time of relapse or till the last 
observation, ranged from 4 weeks to 7 years for both HBeAg and HBV DNA. At start of 
follow-up, groups were comparable regarding sex, age and pre-treatment serum levels of 
HBV DNA and ALT. There were differences in the distribution of race, previous antiviral 
therapy, and participation in a RCT between the 3 groups. 
Figure 1 shows the percentage of sustained HBeAg seroconversion and HBV DNA negativity 
for the total study population by Kaplan Meier analysis. A statistically significant higher 
relapse rate of HBeAg and/or HBVDNA positivity was observed after the end of lamivudine 
monotherapy compared to IFN monotherapy or combination therapy. 
The results of the univariate analysis, shown in table 2, demonstrate that lamivudine therapy, 
male sex, high pre-treatment HBV DNA and low ALT are potential predictive factors for 
relapse of HBeAg and HBV DNA in serum. Age, race, previous antiviral therapy, center and 
study (RCT or cohort study) were not significantly related to the outcome. 
Multivariate Cox analysis stratified by center showed that high pre-treatment HBV DNA, low 
ALT, lamivudine therapy and (male) sex were independent predictive factors of post-
treatment relapse (Table 3). There were no significant interactions. Sensitivity analysis 
excluding each center one at a time gave similar relative risks as the outcome given in table 
3. Subgroup analysis for patients with or without previous antiviral therapy (IFN and/or 
lamivudine) showed equal relapse risks in both groups. In further analysis, race remained 
included because of the unequal distribution across therapies. Patients with a lamivudine-
induced HBeAg seroconversion show a significantly higher risk of relapse compared to 
compared to IFN therapy is 4.6 (95% Cl:1.4-14.5) for lamivudine monotherapy and 0.7 (0.1-
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Table 1 
Baseline characteristics of chronic HBeAg-positive patients prior to succesfull antiviral therapy, by therapy group 
IFN LAM IFN+LAM 
n=49 n=59 n=22 
sex, male 36 (73%) 42 (71 %) 14 (64%) 
age (years)" 41(±16) 37 (± 12) 43 (± 15) 
ethnicity 
Caucasian, other 39 (80%) 19 (33%) 18 (82%) 
Asian 10 (20%) 39 (66%) 3 (14%) 
log HBV DNA"t 8.4 (±1 .0) 8.7 (± 0.8) 8.5 (± 0.8) 
ALT (xULN)" 4.3 (± 2.4) 4.5 (± 4.2) 3.3 (± 2.5) 
previous therapy 
IFN 9 (18%) 26 (44%) 8 (36%) 
LAM 0 (0%) 4 (7%) 1(5%) 
type of study 
RCT1 46 (94%) 10(17%) 15 (68%) 
cohort 3 (6%) 49 (83%) 7 (32%) 
means ±standard deviation 
tcorrected for the HBV DNA test used: Abbott or bONA pg/ml are converted to Eurohep genome equivalents/ml (geq/ml) 
tRCT: randomized controlled trial 
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Figure 1 The cumulative percentage of sustained HBeAg seroconversion (a.) and HBV DNA negativity (b.) for the total study 
population. HBeAg-relapse at 1 year of follow up was observed in 42% of lamivudine, in 21% of IFN and in 23% of 
combination therapy treated patients, increasing to 54%, 32% and 23% respectively after 3 years (p0 .. , 11 =0.01). 
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Table 2 
Univariate analysis (Cox regression) stratified on center. 
Variable HBeAg relapse HBV DNA relapse 
relative risk p-value relative risk p-value 
(95% Cl) (log likelihood) (95% Cl) (log likelihood} 
Therapy 0.0008 0.0005 
IFN 1 1 
LAM 7.4 (2.5-22.4) 0.0003 7.1 (2.4-20.1) 0.0002 
COMBI 1.3 (0.8-4.5) 0.68 1.1 (0.3-3.8) 0.87 
Age (yr) 1.00 (0.98-1.02) 0.87 1.00(0.98-1.03) 0.70 
Sex 
Male 1 
Female 0.4 (0.2-0.9) 0.02 0.5 (0.2-1.1) 0.05 
Race 
Caucasian 1 1 
Asian 0.8 (0.3-2.3) 0.75 1.0 (0.4-2.6) 0.97 
Previous Therapy 0.24 0.05 
None 1 
IFN 1.3 (0.6-2.6) 0.49 1.4 (0.7-2.7) 0.37 
LAM 3.9 (0.8-19.3) 0.11 6.6 (1.4-31.3) 0.02 
Study type 
RCT 1 1 
Cohort 1.3 (0.3-5.6) 0.75 1.85 (0.5-6.8) 0.38 
HBV DNA (log) 1.51 (1.04-2.21) 0.03 1.50 (1.03-2.19) 0.03 
HBV DNA 
HBV DNA <108 1 1 
HBV DNA >108 2.2 (1.2-4.2) 0.01 2.1 (1.1-3.8) 0.02 
ALT 0.04 0.07 
:52 
2-5 0.4 (0.2-0.9) 0.03 0.5 (0.2-1.0) 0.04 
<o5 0.4 (0.1-0.9) 0.02 0.4 (0.2-1.0) 0.04 
Duration of 
lamivudine therapy 0.28 0.22 
24-48 wks 1 1 
48-72 wks 0.4 (0.2-1.2) 0.11 0.4 (0.2-1.1) 0.09 
> 72 wks 0.5 (0.1-2.8) 0.45 0.7 (0.2-2.8) 0.57 
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Table 3 
Multivariate analysis (Cox regression stratified on center and correcting for sex, HBV DNA, AL T and race). 
HBeAg relapse 
Variable RR (95% Cl) 
therapy 
IFN 
LAM 4.6 (1.4-14.5) 
COMB I 0.7 (0.1-3.9) 
'ex 
male 1 
female 0.4 (0.2-0.9) 
race 
Caucasian 
Asian 0.8 (0.3-2.4) 
log HBV DNA 1.61 (1.03-2.52) 
ALT 
<2 
2-5 0.4 (0.2-0.9) 
>5 0.3 (0.1-0.8) 
'" 
"' « ALT<2XULN ID 
<Il 
:c 
'0 ~l ID ~ ~ rn ~ 
"' ~ 
rn 
-s 
E 
0 
u 
HBV DNA relapse 
p-value 
(log-likelihood) 
0.01 
0.01 
0.72 
0.04 
0.74 
0.03 
0.03 
0.02 
0.01 
2xULN_::AL T ~5xULN 
Weeks of follow up 
RR(95%CI) p-value 
(log-likelihood) 
0.01 
1 
3.9(1.3-12.1) 0.02 
0.6 (0.1-2.9) 0.50 
1 
0.5 (0.2-1.2) 0.12 
1 
i .1 (0.4-3.0) 0.84 
1.7 (1.1-2.6) 0.02 
0.05 
0.4 (0.2-0.9) 0.03 
0.4 (0.2-0.9) 0.03 
'";----------------, 
ALT>5xULN 
''" ...,~·::.:~::.::::::::::::::::::.:::: 
........ ~~-- IFN~I.AM 
•a so n a. so 10a 
Figure 2 The cumulative percentage of relapse for the three therapies, corrected for the baseline factors pretreatment HBV 
DNA, AL T, gender and race can be calculated for a specific patient, using the results of the Cox regression (the 
estimated relative risks and the baseline hazard). In this figure the risk is illustrated for a male Caucasian patient with 
a mean pre-treatment HBV DNA level (4x108 geq/mf) after lamivudine, JFN and IFN-Iamivudine combination therapy 
for three different ALT: (a) AL T < 2 x ULN, (b) AL T 2-5 x ULN, (c) ALT > 5 x ULN. Relapse rates are particularly high 
in patients with baseline AL T < 2 x ULN. 
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3.9) for combination therapy (p""'"=0.01).The relative risk of an HBV DNA relapse in serum 
compared to IFN therapy is 3.9 (95% Cl:1.3-12) for lamivudine monotherapy and 0.6 (0.13-
2.9) for combination therapy (p"'""=0.010). The risk of relapse over time for the three 
therapies corrected for pretreatment HBV DNA, gender and any possible race effect can be 
calculated for a given patient. Figure 2 illustrates the risk of relapse rate over time for a male 
Caucasian patient with a mean pre-treatment HBV DNA level (4x108 geq/ml) for 3 different 
categories of baseline ALT. 
The relative risk of relapse after lamivudine therapy was not significantly infiuenced by the 
duration of therapy (p=0.28), but a trend towards a diminished relapse rate with longer 
treatment was found. 
Discussion 
The durability of HBeAg seroconversion after lamivudine therapy was reported to be 80-90% 
in the first studies, performed in Western countries (12,15-16, 19). Recently, Song et al. 
observed a relapse of viral activity in half of responding patients after withdrawal of 
lamivudine monotherapy in an Asian cohort study (17). Ethnicity and duration of therapy prior 
to seroconversion have been suggested to be predictive factors for post-treatment relapse. In 
this study comparing long-term post-treatment data in 130 responders alter lamivudine, IFN 
and IFN-Iamivudine combination therapy, lamivudine induced HBeAg seroconversion was 
significantly less durable than HBeAg seroconversion following IFN-containing therapies, 
independent of race and duration of therapy. However, the pretreatment factors high serum 
HBV DNA and low serumAL T were associated with a higher relapse rate 
The US studies comprised a low number of patients with HBeAg seroconversion, 11 and 5 
respectively with a follow-up of 4 -12 months. The studies reported by Schiff et al. in two 
abstracts only included patients who remained HBeAg negative 3 months alter the end of 
therapy, thereby excluding early relapsers (16). We have tried to increase the accuracy of 
the estimate of the durability of HBeAg seroconversion by including a large number of 
responders in the study, by prolonging the duration of follow-up to 3 years, and by thorough 
statistical analysis. We corrected for differences in baseline characteristics by using 
multivariate analysis. The finding that our results were valid for each center separately 
should markedly increase the confidence in the results. 
However, factors that were no part of the multivariate analysis may still be of relevance. It is 
possible that patients undergoing relapse are more likely to return to their physician than 
patients with a sustained response. We collected data from more than 90% of responder 
patients of the centers that participated, minimizing the likelihood of a selection bias. 
Furthermore, this potential pitfall would affect all three therapies and should therefore not 
influence the relative risk. 
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The HBeAg relapse rate following IFN therapy in this study population (32% in 3 years) may 
appear high. However, when corrected for mean HBV DNA levels and stratified for AL T 
category the post-treatment relapse rate following IFN (figure 2) was in accordance with the 
literature (1-2, 5-10). 
Serum HBV DNA and AL T have been identified as predictors of response to antiviral therapy 
in chronic HBV infection (1, 23). More recently, the degree of ALT elevation was found to be 
the most powerful predictor for HBeAg seroconversion (13, 24). In this study pre-treatment 
HBV DNA levels were the major predictors for sustained response. In contrast to Song (17), 
we also found a significant predictive value of pre-treatment ALT levels for the durability of 
HBeAg seroconversion (higher baseline AL T- lower chance of relapse). 
The differences in relapse following lamivudine and IFN therapy suggest a lack of an efficient 
immune control following HBeAg seroconversion in lamivudine treated patients. Resolution of 
acute hepatitis B is associated with a strong humoral and cellular immune response which is 
often maintained for years by persistence of minute amounts of HBV in liver or serum (25-
27). In contrast to acute HBV infections, chronic HBV is generally associated with a weak 
and ineffective antiviral T-cell response (26, 28). Spontaneous exacerbations and antiviral 
therapy with IFN can elucidate a significant T-helper cell response preceding HBeAg 
seroconversion (29-31). Although Bani et al reported a restored HBV specific T-cell response 
following the strong decline in HBV DNA levels in lamivudine treated patients, HBcAg 
specific T-cell response remained undetectable during lamivudine therapy in another study 
(31-32). The differences in relapse after lamivudine and IFN-therapies in our study suggest 
induction of immune control as an essential element for long-term durability of HBeAg 
seroconversion. 
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Chapter IV.4 
Abstract 
For the treatment of chronic hepatitis B (CHB) two drugs have been licensed world-wide: 
interferon-alpha (IFN) and lamivudine. Both drugs significantly increase the hepatitis B e-
antigen (H BeAg) seroconversion rate, but a sustained response occurs in less than 40% of 
patients. 
To explore whether there is an additional benefit of combining these two drugs, we reviewed 
the literature on lamivudine-IFN combination therapy in comparison to the two 
monotherapies in compensated, HBeAg positive, CHB patients. We focussed on two 
clinically relevant outcome measures: HBeAg seroconversion and change in liver histology. 
Candidates for lamivudine-IFN combination therapy were, previously untreated, patients with 
moderately elevated alanine aminotransferase (AL T). Such regimen should still be 
considered experimental. 
Viral kinetics may provide insight into how long therapy should be continued; prolongation of 
therapy to 52 weeks currently appears a reasonable approach. According to principles of 
anti-viral therapy today, simultaneously dosing of both drugs is to be preferred, since rapid 
maximal virus suppression is thought to be essential to prevent drug resistance and enhance 
seroconversion. From an immunological point of view, pre-treatment with lamivudine or IFN 
may alter the virus-host balance and set the stage for the other drug to enhance the effect of 
treatment. Further clinical research on lamivudine-IFN combination therapy appears 
warranted. 
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Introduction 
For the treatment of chronic hepatitis B (CHB) two drugs have been licensed world-wide: 
interferon-alpha (IFN) and lamivudine. Both drugs have been investigated extensively as 
monotherapy; they significantly increase the HBeAg seroconversion rate, but a sustained 
treatment response occurs in less than 40% of patients. The question arises whether there is 
an additional benefit of combining these two drugs. In this paper, we review the literature on 
lamivudine-IFN combination therapy in comparison to the two monotherapies in 
compensated, HBeAg-positive, CHB patients. We focussed on two clinically relevant 
outcome measures: HBeAg seroconversion, and change in liver histology. 
1. Selection of clinical studies for review 
Pre-treatment patient characteristics, especially levels of alanine aminotransferase (AL T), have 
a major impact on the treatment outcome (1-3). Therefore, different trials should only be 
compared after correction of baseline values. We aimed at including all published large* 
multicenter randomized trials in treatment-naive, HBeAg-positive, compensated, 
immunocompetent, CHB patients with standard lamivudine therapy t;:1 00 mg daily for 52 
weeks), standard IFN (10 MU three times a week (tiw) or 5 MU daily for 16-26 weeks) 
monotherapy and combination therapy of both drugs. In addition to five eligible studies (1-6) we 
have included large international meta-analyses on IFN (7-9); meta-analyses on lamivudine or 
combination therapy are lacking. Furthermore, all other publications on lamivudine-IFN 
combination therapy were assessed. 
2. Hepatitis B e-antigen seroconversion 
2. 1 Standard Therapy 
The HBeAg response in relation to baseline ALT is illustrated in figure 1. 
A large Eurohep meta-analysis of individual patient data, published by Krogsgaard et al (7) in 
1994, showed that the response to IFN therapy is dependent on baseline patient-
characteristics. Often, IFN therapy is said to be associated with loss of HBeAg in 30-40% of 
patients. However, IFN increases the spontaneous response rate, which varies between 5 
and 20%, with a factor 2 resulting in response in 15-40% of patients (1-3). Although the 
relative response is similar for all patients, those with elevated pre-treatment transaminases 
and low baseline HBV DNA levels have the largest absolute benefit from IFN therapy (7, 9-
11 ). 
* more than 40 patients in a treatment arm 
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Figure 1 Overview of treatment results in IFN naive, HBeAg positive chronic hepatitis B patients, by treatment modality; 
relation between baseline AL T and response. 
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Baseline serum aminotransferases (AL T) 
After one year of lamivudine monotherapy, HBeAg seroconversion occurs in maximal 20% of 
patients (2, 4-5). Elevated baseline AL T is also the strongest predictor of lamivudine induced 
HBeAg seroconversion: multivariate analysis showed that both AL T and histologic activity 
index (HAl) were highly significant correlated with HBeAg seroconversion, but the contribution 
of HBV DNA to the predicted response was negligible (12). Lamivudine increases the response 
rate with a factor less than 2 in case of AL T < 2 times the upper limit of normal (ULN), but this 
factor rises to 4 in case of AL T > 5 x ULN (2-3). 
The efficacy of lamivudine-IFN combination therapy given for 16 weeks after 8 weeks of 
lamivudine pre-treatment, was compared to standard IFN (10 MU tiw for 16 weeks) and 
lamivudine (100 mg qd for 52 weeks) monotherapy in 230 treatment-naive HBeAg-positive 
patients. Combination therapy resulted in a HBeAg seroconversion rate of 29% in the intention-
to-treat analysis. This outcome was not significantly higher than after IFN (19%) or lamivudine 
(18%) monotherapy. However a per-protocol analysis, excluding all patients who did not meet 
the inclusion criteria at baseline or receive the assigned treatment, revealed a significant higher 
seroconversion rate in the combination group. Thirty-six percent of patients receiving 
combination therapy responded versus 19% and 22% in the lamivudine and IFN monotherapy 
groups, respectively (2). 
In this study, a subgroup analysis based on pre-treatment AL Twas performed, showing a 2-6-
fold increase in the seroconversion rate in patients receiving combination therapy over that 
expected spontaneously. The absolute increase in the response was most pronounced in the 
group with moderately elevated AL T levels (2-5 x ULN). For patients with moderately elevated 
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pre-treatment serum transaminases, combination therapy may have a benefit over 
monotherapy. 
2.2 Prolongation of therapy 
Prolongation of both IFN and lamivudine leads to increased HBeAg seroconversion rates. 
Prolongation of IFN therapy from the standard 16 to 32 weeks enhanced clearance of HBeAg 
and HBV DNA in patients with HBV DNA levels below 10 pg/ml (Abbott assay) at 16 weeks of 
therapy (6). 
Extension of lamivudine therapy from the standard 1 year to 2 years was associated with a 
modest increase in response to 21-27% (13-15). In an Asian study, continuation for 4 years in 
58 patients showed an increased HBeAg seroconversion rate of 47% (16). However, the 
definition of HBeAg seroconversion was altered in this study concentrating on HBeAg 
negativity independently of HBV DNA negativity. In nearly half of these responders a YMDD 
variant was detectable (16). The emergence of lamivudine resistant strains is a major problem 
of long-term therapy; it has been reported in up to 60% of Caucasians at 2 years of therapy 
and 40-55% of Asian patients at 2-3 years (14-15, 17). 
Prolonged combination therapy of IFN and lamivudine has not been investigated yet, with the 
exception of some cases. Figure 2 illustrates a case of a young woman receiving lamivudine 
150 mg daily for 1 year simultaneously with IFN 10 MU tiw till week 32, followed by 5 MU tiw up 
till 1 year. This patient seroconverted and lost hepatitis B surface antigen (HBsAg). The 
response was sustained after withdrawal of therapy during the follow-up of 1 year. 
2.3 Durability of response 
HBeAg seroconversion, either spontaneously or following IFN therapy, significantly reduces 
morbidity and mortality (11, 18-19). 
Several long-term follow-up studies have been performed to establish the durability of IFN 
induced HBeAg seroconversion and the effect of the durability of the response on disease 
progression and survival (8, 11, 18, 20-24). Responders to IFN therapy have a significantly 
lower risk to develop cirrhosis (22). In addition IFN has been identified as an independent 
factor related to a decreased risk for HCC development (22). Survival is found to be improved 
in 5 out of 6 studies assessing the impact of HBeAg seroconversion (8, 11, 18, 20-22). In 
cirrhotic patients IFN induced viral clearance improves survival, although Cox regression 
revealed ALT as the most important predictor of improved survival in these patients (21-22). 
IFN induced HBeAg seroconversion is sustained in around 90% of patients (Fig 2) (8, 11, 18, 
20, 22-24). 
Lamivudine induced HBeAg seroconversion is suggested to be comparable to HBeAg 
seroconversion after IFN therapy (13, 16, 25). Forty-three lamivudine responders (defined as 
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HBeAg negative and detectable anti-HBe, or HBeAg and HBV DNA negative (bONA) patients) 
were followed for a median of 21 months after cessation of therapy; only 19% (8142) relapsed 
(25). This encouraging report, however, needs confirmation, since the patient population was 
highly selected from several lamivudine trials, by including only patients who remained 
responders for at least 3 months off lamivudine or who had seroconversion maintained on at 
least 2 occasions off therapy over time. In contrast to these reports, single-center cohort 
studies show a relapse percentage that increases with time of follow-up (26-27). One study 
comprising 34 responders (HBeAg negative and anti-HBe positive) to lamivudine therapy 
reported a cumulative relapse percentage up to 49% at 2 years of follow-up (26). Figure 3 
shows the durability of HBeAg seroconversion during long-term follow-up after withdrawal of 
lamivudine or IFN therapy. 
No long-term follow-up data after combination therapy induced HBeAg seroconversion are 
available. 
3. Improvement of liver histology 
Figure 4 illustrates effect of various therapies on the necro-infiammatory component of the 
Knodell scoring system (0-18 points). Histological improvement is defined as more than 2 
points reduction of the necro-inflammatory score. An important factor, hampering the 
comparison of histological results of lamivudine with other therapies in several larger studies, 
is the fact that all biopsies were taken at the end of lamivudine monotherapy but 6 months 
after withdrawal of IFN or combination therapy. 
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Figure 2 Prolonged combination therapy of lamivudine and IFN for 52 weeks 
in an individual Caucasian woman of 23 years. Note the complete 
response occurring during therapy. 
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Figure 3 Durability of HBeAg seroconversion after withdrawal of monotherapy with IFN 
or lamivudine during long-term follow up. In case the follow up after 
withdrawal of IFN therapy was beyond 5 years, the line was cut off at 5 years. 
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Lamivudine significantly reduced the HAl score and prevented progression of fibrosis in HBeAg 
positive patients at 1 year of therapy (2, 4-5, 28-29). Results following withdrawal of lamivudine 
therapy are not available. Lamivudine shows histological benefit in about 50% of the patients, 
whereas IFN therapy showed improvement in 45% and combination therapy in 38% of 
patients. The difference between active treatments appears more clear when disease 
progression is taken as the outcome measure: the number of patients with worsening of 
histology during lamivudine is minimal (7-11 %), whereas IFN, combination therapy and 
placebo were associated with worsening of histology in about one-third of patients. 
The differences between lamivudine and IFN can be partially explained by the fact that these 
are overall results, including responders as well as non-responders to therapy. In IFN and 
combination therapy, histological improvement is dependent on a virological response (2, 4, 
30). 
4. Safety 
Combination therapy with IFN and lamivudine up to 26 weeks is generally well tolerated (2, 31-
33). Combining both drugs does not change the safety profile; side effects are mainly IFN 
related (2, 33). IFN has a wide range of dose-depending side effects, which requires dose 
reduction in 20-40% of the patients and discontinuation in about 5% of the patients (1-2, 6,9). 
No pharmacokinetic interactions, that might affect the efficacy of both drugs, were observed 
during co-administration (32). Stopping lamivudine, also as part of combination therapy, is 
associated with a slightly increased risk of post treatment flares in around 20% of patients (2, 
33-34). 
5. Other experiences with combination therapy in chronic hepatitis B 
The enhanced seroconversion rate for combination therapy, as reported by Schalm et al (2), 
could not be confirmed in a study of 238 HBeAg positive, previous IFN non-responders (33). 
Compared to the study in treatment-naive patients a similar trial design was used; only the arm 
with IFN-monotherapy was replaced by placebo. At week 52, 12% of patients receiving 
combination therapy seroconverted for HBeAg, which was comparable to placebo (13%) but 
lower than lamivudine (18%) therapy. 
The reason for the lack of response to lamivudine-IFN therapy most likely relates to patient 
characteristics. A subgroup analysis based on pre-treatment AL T is lacking, but median 
baseline AL T and HBV DNA levels were comparable in both studies. In general, host immunity 
was not overall low, in view of the response rate in the placebo and lamivudine groups. It is, 
however, conceivable that previous IFN non-responders have an immune status that makes it 
very difficult to respond to 16 weeks of IFN, even in the presence of lamivudine therapy. 
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Another study in 20 previous I FN non-responders, receiving combination therapy, showed a 
response in 20% of patients (32). This response was sustained in only 1 out of 4 patients. In a 
third study in previous non-responders, 6 months of lamivudine followed by 6 months of IFN 
led to a sustained response in 45% of patients, but this needs further investigation (35). Finally, 
a study of 26 weeks of combination therapy in HBeAg-negative patients resulted in HBV DNA 
PCR negativity in 95%; however, withdrawal of combination therapy for this time period often 
led to a relapse of viral activity (31). 
Conclusions and implications for future research 
The relatively low sustained response rates with either IFN or lamivudine monotherapy, the 
possibility of relapse of viral activity after cessation of lamivudine monotherapy and the time-
dependent emergence of viral resistance to lamivudine emphasize the need for combination 
therapy. 
In previously untreated patients, those with moderately elevated AL T are candidates for 
lamivudine-IFN combination therapy. Such regimen should still be considered experimental. 
Viral kinetics may provide insight how long therapy should be continued; prolongation of 
therapy to 52 weeks currently appears a reasonable approach. According to principles of 
antiviral therapy today, simultaneously dosing of both drugs is to be preferred, since rapid 
maximal virus suppression is thought to be essential to prevent drug resistance and enhance 
seroconversion. From an immunological point of view, pretreatment with lamivudine or IFN 
may alter the virus-host balance and set the stage for the other drug to enhance the effect of 
treatment. Further clinical research on lamivudine-interferon combination therapy appears 
warranted. 
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V. DISCUSSION AND FUTURE IMMUNE MODULATORY STRATEGIES IN THE 
TREATMENT OF CHRONIC HEPATITIS 8 
Chapter V. 
Natural history of chronic hepatitis B 
Worldwide over 350 million people are infected with the hepatitis B virus (HBV), which is the 
major cause of liver related deaths. Of all chronically infected HBV patients, between 10-30% 
have active chronic liver disease (1-2). 
Inactive chronic HBV carriers (immune control phase, table 1) have an uneventful long-term 
prognosis; cirrhosis is not likely to develop, the yearly incidence of HCC is 0,1% and their 5-
year survival rate is comparable to the normal population (97%) (3-6). Although low levels of 
viral replication may persist, there is no indication for antiviral therapy (7 -8). 
Active HBV on the other hand is often a progressive disease leading to liver cirrhosis and 
hepatocellular carcinoma (HCC) after 10 to 30 years. The progression rate of chronic liver 
disease to cirrhosis is 2-4% per year and eventually 20-35% will develop cirrhosis (5, 9-11). 
The annual HCC rate is 1%, increasing to 2-10% in cirrhotics (5, 11 ). The 5-year survival rate 
is decreased to 86%, which may decrease further to less than 35% after liver 
decompensation (4, 12-13). 
The loss of active HBV replication, reflected by loss of HBeAg from serum and normalization 
of serum transaminases, is an important factor significantly improving morbidity and mortality 
in cirrhotic as well as non-cirrhotic patients (14-17). Moreover one study identifies 
biochemical disease remission as the best positive predictor of improved survival in 
compensated cirrhosis (18). 
Obviously the primary goal of antiviral therapy in chronic HBV is sustained inactivation or 
elimination of HBV and biochemical disease activity. Therapy is targeted to those patients 
with active HBV, HBeAg positivity in combination with high HBV DNA and AL T levels 
(immune elimination phase) or in those infected with a precore mutant (immune escape 
phase), high HBV DNA and AL T levels. The benefit of antiviral therapy in immune tolerant 
patients is unclear. 
Table 1 
Selection of chronic HBV patients for antiviral therapy based on virological and biochemical parameters. 
Phase of Immune activity: Tolerance Elimination Control or Escape 
Residual 
Virological HBeAg + + --
HBVONA 10 geq/ml 10 ~10 geq/ml <10 geq/ml >10 geq/ml 
Biochemical ALT <ULN j <ULN j 
ALT>SxULW + + 
Prevalence 10% 10% 60% 10% 
Advice on antiviral Rx (+) + + 
* HepatitiS flare followed by HBeAg seroconversion 1n 25% 
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Table 1 illustrates the selection of HBV patients for antiviral therapy based on virological and 
biochemical parameters. In this thesis we focussed on how to improve standard antiviral 
therapy. In addition we tried to identify patients who benefit most from therapy. 
The basis of antiviral therapy in HBV 
The first agent licensed for the treatment of HBV was interferon-alpha (IFN). IFN is a natural 
glycoprotein with direct antiviral and immunostimulating properties (see chapter 1). 
Sustained IFN responders have a significantly improved morbidity and mortality (11, 14-15, 
18, 19). However, IFN monotherapy induces HBeAg seroconversion in maximal 20% of 
patients with low baseline AL T levels to 40% of patients with activated baseline host 
immunity (20). The biochemical remission parallels the virological response in 94% of 
patients (21). Response is sustained in approximately 90% of patients (14-15, 18-19, 21-24). 
Patients with high HBV DNA levels and low AL T levels before start of interferon therapy are 
unlikely to respond. Immune tolerance is probably induced by an abundance of viral particles 
and proteins creating an unfavorable position for interferon to restore the T-cell 
hyporesponsiveness characteristic for chronic HBV. 
Since the end of 1999 lamivudine has been registered for the treatment of chronic HBV. 
Lamivudine is a cytidine dideoxynucleoside analogue that acts as a chain terminator after 
incorporation in the viral DNA and is a strong virus suppressive agent. 
Hypothetically maximal virus suppression by lamivudine therapy could enable the host 
immune response to restore and eliminate the virus infected cells over time. However loss of 
HBeAg and gain of anti-HBe is described in only 20% of patients at one year of lamivudine 
monotherapy (25-26, 27). More important we showed that lamivudine induced HBeAg 
seroconversion is significantly less durable compared to HBeAg seroconversion following 
IFN-containing therapies and withdrawal is mostly followed by virus return. On the other hand 
prolongation is hindered by the development of resistant strains, documented in more than 
half of all patients after 2 to 3 years of therapy (28-30). 
The limited effect of lamivudine monotherapy is probably due to the fact that lamivudine does 
not affect the ccc-DNA pool and is dependent of the host immune response for viral 
elimination. As for IFN therapy patients with higher baseline AL T levels are more likely to 
have a sustained response to lamivudine therapy. On the other hand those with low AL T 
levels are unlikely to respond and have higher relapse rates (27, this thesis). Strong 
suppression of HBV replication reduces the expression of epitopes of viral proteins on the 
cell surface, hampering the class !-mediated CDS+ CTL response. In patients with no 
baseline host immune reactivity, it is therefore very unlikely the T-cell hyporesponsiveness 
will be restored during lamivudine therapy as has been published earlier (31 ). This may 
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account for the high relapse rate reported by others and us and suggest additional immune 
modulating therapy is necessary to obtain viral elimination (32, this thesis). 
How to improve antiviral therapy in chronic HBV 
Combination therapy seems the way to go. Several approaches aiming to improve the 
efficacy of antiviral therapy have been investigated or suggested. 
a. Combination of nucleoside analogues 
Several other nucleoside analogues including famcyclovir, adefovir dipivoxil, emcitabine, 
entecavir, clevudine among others, are available. The combination of 2 or more nucleoside 
analogues, acting complementary with regard to inhibition of the viral polymerase and viral 
replication, is likely to obtain long-term control of HBV. Not only the degree of HBV 
suppression will be increased, this approach may also prevent viral resistance as has been 
successfully shown in HIV (33). 
The combination of lamivudine with famciclovir, a relatively weak HBV suppressive drug, for 
12 weeks showed to significantly increase the inhibition of viral replication (34). Both adefovir 
dipivoxil and entecavir appear to be effective in patients with lamivudine resistant HBV 
mutant strains (35). 
Th goal of combined nucleoside combination therapy would be obtaining sustained long term 
virus suppression. In the absence of host immune activity, it is very unlikely a combination of 
nucleoside analogues will actively eliminate HBV infected cells and subsequently ccc-DNA, 
the template for transcription of pregenomic RNA. Only of one of the newer compounds, 
entecavir, it is claimed it does affect the ccc-DNA pool in woodchucks (30-37). 
b. Combination therapy of lamivudine and anti-HBs 
Anti-HBs is well known in the prevention of perinatal transmission, post-exposure prophylaxis 
and post-liver transplantation but relatively unexplored in the treatment of chronic hepatitis B. 
The major effect of anti-HBs is preventing transmission of HBV by binding and neutralizing 
circulating HBsAg. In addition suggested immunomodulatory effects of antibodies in chronic 
hepatitis include antibody-dependent cellular cytotoxicity (ADCC), modulation of antigen 
presentation leading to stimulation of production of pro-inflammatory cytokines, formation of 
antigen-antibody complexes preventing infection and promoting opsonization by macrophages, 
and interference with the assembly and secretion of HBsAg (38-45). 
We showed the administration of anti-HBs in vivo, both of HBig and MAb, can induce a 
temporary reduction and neutralization of HBsAg in lamivudine treated patients. Although in 
preclinical studies MAb showed a 200-times higher affinity for HBsAg compared to HBig, our 
in vitro results showed nearly 100% inhibition of HBsAg by HBig, the MAb however was only 
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partially effective. Galun et al showed comparable results in patients not pretreated with 
lamivudine using a mixture of two monoclonal antibodies (46). He also observed a reduction 
in HBV DNA. These two antibodies were tested previously in a trimera mouse model 
showing an inhibition of viral replication and reduction of viral load. 
Galun et al suggested to add anti-HBs to lamivudine treated patients (46). In our trials 
however this appeared an unsuccessful strategy. This is probably because infection of 
hepatocytes may be interrupted by infusion of anti-HBs, but there will still be a reservoir of 
infected cells, which will not be removed. Furthermore despite lamivudine pretreatment there 
are still high amounts of anti-HBs necessary, increasing the risk of side effects and 
inconvenience due to the amount of infusions. Lamivudine therapy blocks viral replication 
and the amount of Dane-particles is reduced. Although it was less accurate investigated as 
for IFN, this is accompanied by a considerable decrease in HBsAg levels but still relatively 
high levels were detectable (47-48, this thesis). 
The development of a monoclonal directed against the Dane particle preventing viral spread 
would possibly be more effective in combination with intermittent low dose lamivudine 
therapy. 
c. Combination therapy of lamivudine and /FN 
We showed combining lamivudine and IFN drugs may increase the initial response rate if 
given for a prolonged period of time. According to these data the duration of combination 
therapy given in the previous trials was way to short explaining in part the limited efficacy 
reported up till now (27, 49-50). One trial using 24 weeks of combination therapy showed to 
indeed increase the efficacy (51). 
It has to be taken into account these data were obtained using a biphasic viral kinetic model 
designed for IFN therapy in HCV. However it was previously shown it fits data obtained 
during lamivudine therapy in chronic HBV very well (52). Secondly we did not have multiple 
measurements in the first phase, therefore we had to focus on the second phase. At last no 
long-term data were available and the estimated time to viral negativity was calculated by 
extrapolation of the second phase. It is however possible the model may be accurate for 
long-term therapy or there may be a third phase when extending therapy, this has not been 
investigated yet during antiviral therapy for chronic HBV. Future viral kinetic studies using 
multiple measurements during the first phase and extending of the model beyond 16 weeks 
is necessary. 
Combining IFN and lamivudine significantly decreased the relatively high relapse rate 
observed after lamivudine monotherapy (this thesis). In general patients with high pre-
treatment HBV DNA and low ALT levels pretreatment are at higher risk for post treatment 
relapse of viral activity. The positive correlation between higher AL T, response and HBV 
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DNA decline was shown already before (20, 27, this thesis). Targeting combination therapy 
to this group of patients will significantly increase efficacy and reduce relapse rates. The 
identification of other baseline factors such as genotype is important. The clinical significance 
of hepatitis B genotypes is still unclear although there is growing evidence for the correlation 
with HBeAg seroconversion, progression of liver disease, the occurrence of YMDD mutations 
and certain subtypes (53-56). 
The optimal schedule of lamivudine-IFN therapy is unclear yet. Previously it was shown that 
pretreatment with IFN before initiation of lamivudine therapy only delayed the effect of 
combination therapy on HBV DNA levels (50). Lamivudine pretreatment has been suggested, 
although the partial overlapping treatment schedule described was unsuccessful. This was 
nevertheless in contrast to previously published results (57). Intermittent lamivudine therapy 
would probably face the same problems as partial overlapping schedules. 
Based on the reports on combination therapy an international multi-center study was started. 
Because of the strong effect of the pretreatment AL T level on the initial response rate and its 
positive effect on prevention of post-treatment relapse, we focussed on those patients with 
elevated AL T levels. This study investigates the efficacy of 52 weeks of combination therapy 
in immune reactive patients reflected by elevated pre-treatment AL T levels; first results are 
expected within the coming year. Future studies will have to determine the optimal duration 
of combination lamivudine-IFN therapy and therapeutic schedule. 
Since a new array of new nucleoside analogues with similar or even stronger antiviral effect 
compared to lamivudine, are in use or under development we may expect several 
combinations with IFN in the future. The combination of pretreatment with L-FMAU followed 
by surface antigen vaccination was able to disrupt immune tolerance in woodchucks (58). 
This may support the hypothesis sequential or intermittent nucleoside analogue treatment 
followed by immunomodulating therapy may be effective. 
d. Other immune modulating drugs 
Although no conclusive results on monotherapy with recombinant anti-HBV, specific T cell or 
DNA vaccines, thymosine a and specific cytokines are available so far, combination with 
these drugs and new nucleoside analogues in the future may increase the efficacy of antiviral 
therapy (see chapter 1) (59-64). 
e. New developments 
Recently the use of hammerhead ribozyme-mediated gene therapy has been introduced as a 
potential novel therapeutic agent. Specific ribozymes mediated cleavage of HBV RNA 
reduces HBV replication in vitro in HepG2 cells (65). 
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In conclusion 
Future studies need to take into account baseline factors like AL T and HBV DNA and 
probably genotype to evaluate and target antiviral therapy. The use of viral kinetics may give 
more lucidity about the effect and duration of therapy needed. 
Combination therapy of immunomodulating drugs and nucleoside analogues is necessary to 
improve effectivity, break immune tolerance and prevent relapse in chronic HBV. 
Lamivudine-IFN is a potent combination especially in patients with elevated baseline AL T, 
the optimal duration and the use of an overlapping or sequential schedule are still unclear. In 
patients with low immune reactivity a combination with several nucleoside analogues may 
obtain long-term virus suppression. 
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Summary 
The search for antiviral agents in chronic hepatitis B virus (HBV) infected patients faces 
multiple problems. Monotherapy with either alpha-interferon (IFN) or lamivudine has limited 
efficacy; viral clearance -loss of HBeAg and gain of anti-HBe- is the result in only 20-40% of 
patients. Although nucleoside analogues are very potent inhibitors of viral replication, viral 
resistance complicates long-tenm therapy, whereas withdrawal is followed by a relapse of 
viral replication and inflammatory activity. This stresses the need for new therapeutic 
approaches. 
The studies presented in this thesis focus on combination of immune-modifying drugs (anti-
HBs and IFN) and the nucleoside analogue lamivudine in chronic compensated HBV 
patients. Theoretically this approach may increase the HBeAg seroconversion rate and 
enhance sustained viral clearance by combining strong initial virus suppression and immune-
mediated clearance of remaining infected cells. The correlation between pre-treatment 
patient characteristics -especially AL T levels- and the degree of virus suppression, response 
and post-treatment relapse rate was investigated in more detail. These data may better tailor 
antiviral therapy to subgroups of HBV infected patients. 
Although anti-HBs is used extensively in the post-transplantation period in HBV, in only 3 
small trials it was used for the treatment of chronic HBV. In chapter II, three studies are 
described using polyclonal antibodies (HBig, Hepatect®) or a human monoclonal anti-
hepatitis B antibody preparation recognizing the stable 'a'-determinant of the HBsAg 
molecule (MAb) in chronic HBV patients. After infusion of anti-HBs, antigen-antibody 
complexes are formed rapidly, theoretically preventing the spread of the virus to non-infected 
cells. In addition these complexes have been described to promote opsonisation increasing 
the uptake by macrophages and enhance the HBsAg specific T-cell response. In theory 
monoclonal antibodies may also have specificity to certain determinants involved in binding 
or penetration of the virus. 
The first study describes 10 chronic HBV patients, 4 received the MAb and 6 a combination 
of IFN plus the MAb (chapter 11.1). Although a reduction in HBsAg levels of more than 50% 
was achieved in all patients, neutralization of circulating HBsAg was not obtainable. No long-
term effects were observed despite in 3 patients treated with combination therapy. In these 
patients serum HBV DNA levels became undetectable, however this effect probably has to 
be attributed to IFN. 
The last 2 studies describe the effects of HBig respectively MAb in chronic HBV patients pre-
treated with lamivudine to obtain maximal viral load reduction (HBV DNA levels undetectable 
by hybridization assay). Experimental enzyme-immunoassays (EIA's) were developed to 
evaluate the neutralizing efficacy of the MAb in the circulation. With monoclonal antibody 
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conjugates HBsAg, MAb and HBsAg-MAb complexes were measurable in serum seperately. 
In vitro HBig showed complete neutralization, whereas the Mab was only partially effective. 
In vivo the neutralizing effect of HBig was limited to those patients with very low HBsAg 
levels. The MAb, which has a 200-fold binding capacity compared to HBig, also only showed 
a temporary HBsAg neutralizing effect also related to pretreatment HBsAg levels. During 
MAb therapy the antibody could be detected in circulating HBsAg/anti-HBs complexes. No 
long-term effects were observed. Unfortunately passive immunization, even in HBV DNA 
PCR negative patients, was not a feasible option. 
In chapter Ill a case is described of a chronic HBV patient on lamivudine therapy, 
superinfected with the hepatitis A virus (HAV). After 8 weeks of lamivudine monotherapy the 
initial fast drop in HBV DNA ceased and levels around 107-106 geq/ml remained detectable. 
A sudden further decline of HBV DNA below the limit of detection of the assay (400 geqlml) 
and the loss of HBeAg from serum following a peak of serum transaminases, accompanied 
an acute HAV infection. The induction of a HAV mediated IFN-gamma peak just before the 
rise in serum transaminases, was pivotal in the additional suppression of HBV DNA 
replication. Several other cytokines -IFN-alpha, TNF-alpha and IL-12- remained 
undetectable; a small IL-10 peak was measurable which could have contributed to the self-
limitation of the response. No HBV-specific T cell response was elucidated. This probably 
accounts for the relapse of viral activity after resolution of the HAV infection and withdrawal 
of lamivudine therapy, despite the temporary addition of IFN-alpha therapy. 
The potential benefit of lamivudine-IFN combination therapy in chronic HBV was evaluated in 
four studies described in chapter IV. Several studies on combination therapy were published 
previously. Although in 2 studies an enhanced HBeAg seroconversion rate following 
combination therapy was reported compared to monotherapy with either lamivudine or IFN, 
the overall results remained disappointing. Combination therapy appears to be the most 
beneficial approach in patients with elevated baseline ALT levels (2-5 x ULN) (chapter IV.4). 
We tried to optimize the effect of combining both drugs by using a different treatment 
schedule, our initial hypothesis being that by viral load reduction IFN efficacy might be 
enhanced. IFN was added after at least 16 weeks of lamivudine monotherapy (chapter IV.1). 
Combination therapy was given for at least 8 weeks followed by withdrawal of lamivudine, 
IFN monotherapy was continued for at least 8 weeks. During lamivudine monotherapy HBV 
DNA levels decreased a median of 3.2 logs, 66% of final decrease was obtained in the initial 
4 weeks. Thereafter the decline of HBV DNA was more gradual (0.2-0.3 logs per month). 
Adding IFN further increased the degree of virus suppression by a median of 1.4 log, 86% 
was obtained in the first 4 weeks of combination therapy. However withdrawal of lamivudine 
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and subsequently IFN was accompanied by a relapse of viral activity in most patients. 
HBeAg seroconversion was obtained in 4/24 patients, this was sustained in only 2/24 
patients (8%). Although the degree of virus suppression was superior during lamivudine-IFN 
combination therapy, at the end of follow-up no additional benefit was observed using the 
schedule studied. 
In the second study the effect of combination therapy was further evaluated using a biphasic 
mathematical model (chapter IV.2). It was shown that combining both drugs enhanced the 
decay rate of HBV DNA from serum during both phases of viral decline. Simultaneously 
dosing of IFN and lamivudine decreased the half-life of the virus and of the infected cell 
significantly. Independently of the therapy given, a significant correlation between baseline 
ALT levels and the decline rate of HBV DNA levels was found. More importantly 
extrapolation of the second phase of the bi-phasic model showed that, theoretically, 
combining both drugs will reduce the estimated time needed to obtain serum viral elimination 
and it will increase the percentage of patients that may reach this point to nearly 100%. 
Although short-term combination therapy (16 weeks) did not increase efficacy in previous 
studies these results suggest a strong benefit of combination therapy over monotherapy with 
either drug when given for a prolonged period of time. 
There is a debate about the durability of lamivudine induced HBeAg-seroconversion. A large 
international multicenter meta-analysis of individual patient data following IFN, lamivudine or 
lamivudine-IFN therapy induced HBeAg-seroconversion was designed (chapter IV.3). At 3 
years of follow-up a relapse of HBeAg in serum was observed in 54% of responders to 
lamivudine therapy compared to 32% following IFN and 23% following combination therapy. 
High ALT levels and low HBV DNA levels were positively related to lower relapse rates, 
independently of the therapy given. Correction for baseline factors, HBV DNA, AL T, race and 
sex, further increased the relapse risk following lamivudine therapy and decreased the risk of 
post-treatment relapse after IFN-containing therapies. The relative relapse risk of HBeAg 
after withdrawal of lamivudine was 4.6 compared to IFN monotherapy. So these results 
clearly show lamivudine induced HBeAg-seroconversion is significantly less durable 
compared to seroconversion following IFN-containing therapies. 
Long-term lamivudine-IFN combination therapy will probably increase the initial response 
rate substantially, decrease the duration of therapy needed and minimize the risk of relapse 
of viral activity after withdrawal of therapy compared to monotherapy with either drug, 
especially when targeted to patients with elevated baseline serum transaminases. The effect 
of long-term combination therapy in different patient populations and the optimal treatment 
schedule, dose and duration of therapy will be subjects of future studies. 
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In de zoektocht naar antivirale middelen voor de behandeling van patienten chronisch 
gefnfecteerd met het hepatitis B virus (HBV) stuit men op multiple problemen. Monotherapie 
met interferon-alpha (IFN) of lamivudine heeft een beperkte effectiviteit; slechts in 20-40% 
van de patienten wordt klaring van het virus -verlies van HBeAg en aanmaak van anti-HBe-
bereikt. Ondanks dat nucleoside analoga een sterke virus onderdrukkende werking hebben, 
wordt behandeling op de langere duur beperkt door het ontstaan van virale resistentie, terwijl 
aan de andere kant het stoppen van behandeling gepaard gaat met de terugkeer van het 
virus in serum en opvlamming van de ontstekingsactiviteit. Bovenstaande benadrukt de 
noodzaak van een nieuwe therapeutische aanpak in chronische HBV. 
De studies die in dit proefschrift gepresenteerd worden richten zich op het gebruik van een 
combinatie therapie van immuunmodulerende middelen (anti-HBs en IFN) en nucleoside 
analoga in chronische gecompenseerde HBV patienten. Theoretisch kan de combinatie van 
sterke initiele virus onderdrukking met immuun gemedieerde opruiming van gerntecteerde 
cellen leiden tot een verhoogd percentage HBeAg seroconversie en blijvende virale klaring. 
Patientenkenmerken voor start van therapie -met name AL T- zijn onderzocht in relatie tot de 
mate van virus suppressie, het percentage respons en terugkeer van het virus na stoppen 
van therapie. Op basis van deze data kan de therapie beter gericht worden op bepaalde 
subgroepen van patienten. 
Alhoewel het gebruik van anti-HBs uitgebreid onderzocht is in de periode na 
levertransplantatie, is het effect in chronische HBV slechts in drie kleine onderzoeken 
beschreven. In hoofdstuk II worden drie nieuwe studies beschreven die het gebruik van 
polyclonale antilichamen (HBig, Hepatect®) of van een humaan monoclonaal anti- hepatitis 
B antilichaam (MAb) gericht tegen het stabiele deel van het HBsAg molecuul, "a-
determinant", in chronische HBV bestuderen. Na infusie van anti-HBs vormen zich snel 
antigeen-antilichaam complexen welk theoretisch de verspreiding van het virus naar niet-
ge"infecteerde cellen voorkomt. Daarbij is beschreven dat deze complexen de "opsonisatie" 
stimuleren en zo de uptake door macrophagen vergroot en de HBsAg specifieke T-cell 
response stimuleren. In theorie kunnen monoclonale antilichamen ook specifiek gericht zijn 
tegen bepaalde delen die betrokken zijn bij de binding en penetratie van het virus. 
De eerste studie beschrijft lien chronische HBV patienten, vier werden behandeld met he! 
MAb en zes met IFN-MAb combinatie therapie (hoofdstuk 11.1). Hoewel een reductie van 
HBsAg met meer dan 50% werd bereikt in aile patienten, was neutralisatie van circulerend 
HBsAg niet haalbaar. Er werden geen lange termijn effecten waargenomen, behoudens in 
drie patienten die behandeld werden met combinatie therapie. In deze groep werd serum 
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HBV DNA ondetecteerbaar. He! is echter mogelijk dat dit effect aan de werking van IFN 
aileen kan worden toegeschreven. 
In de laatste !wee studies word! het effect van HBig respectievelijk MAb beschreven in 
chronische HBV patienten die zijn voorbehandeld met lamivudine om een maximale reductie 
van de virale load te verkrijgen (HBV DNA negativiteit gemeten met een hybridisatie test). 
Experimentele enzyme-immunoassays (EIA's) werden ontwikkeld om de HBsAg-
neutralizerende werking van het MAb in de circulatie te evalueren. Met monoclonale 
antilichaam conjugaten werd he! mogelijk om HBsAg, MAb en HBsAg-MAb complexen apart 
te meten. In vitro was het mogelijk complete neutralisatie te verkrijgen met HBig, echter MAb 
was slechts gedeeltelijk effectief. In vivo was he! tijdelijke neutraliserend effect van HBig 
beperkt tot die patienten met zeer lage HBsAg waarden. Met he! MAb, wat een 200 maal 
sterkere binding van HBsAg ten opzichte van HBig vertoont, werd oak slechts tijdelijke 
HBsAg neutralisatie bereikt hetgeen oak gerelateerd was aan lage HBsAg waarden voor 
start van de behandeling. Gedurende de behandeling met MAb kon het MAb ge'identificeerd 
worden in circulerende HBsAglanti-HBs complexen. Er zijn geen lange termijn effecten 
waargenomen en he! bleek dat passieve immunizatie, zelfs in HBV DNA PCR negatieve 
patienten geen haalbare optie was. 
In hoofdstuk Ill word een casus beschreven van een chronische hepatitis B patient 
ge'infecteerd met he! hepatitis A virus (HAV) tijdens behandeling met lamivudine. Na 8 
weken behandeling met lamivudine buigt de initiele snelle daling van het HBV DNA zich af 
en blijft op ongeveer 107-106 geqlml hangen. Volgend op een acute HAV infectie gepaard 
gaande met een piek in serum transaminasen treed! een plotselinge snelle daling van HBV 
DNA op tot beneden de detectielimiet van de test (400 geqlml) alsmede he! verlies van 
HBeAg. He! induceren van een HAV gemedieerde IFN-gamma piek net voor de snelle 
stijging van serum transaminasen, bleek een essentiele rol te spelen in de additionele 
suppressie van HBV DNA replicatie. Verschillende andere cytokines -IFN-alpha, TNF-alpha 
en IL-12- bleven negatief; een kleine piek in IL-10 was meetbaar hetgeen theoretisch kan 
hebben geleid tot een gelimiteerde respons. Er werd geen HBV specifieke T-cell response 
gegenereerd, hetgeen waarschijnlijk de terugkeer van he! virus na beeindiging van de HAV 
infectie en het stoppen van lamivudine, verklaart, ondanks de tijdelijke toevoeging van IFN. 
In hoofdstuk IV worden vier studies beschreven die he! potentiele effect van lamivudine-IFN 
combinatie therapie in chronische HBV bestuderen. Voorheen zijn verschillende lamivudine-
IFN studies verricht. Alhoewel in !wee studies een toegenomen HBeAg seroconversie werd 
beschreven na combinatie therapie in vergelijking met IFN of lamivudine monotherapie, blijft 
de meerwaarde van combinatie therapie vooralsnog onduidelijk en zijn de resultaten in het 
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algemeen teleurstellend. Combinatie therapie heel! he! grootste effect in patienten met een 
middelmatig verhoogde AL T (2-5 keer de bovengrens van normaal) voor start van therapie 
(hoofdstuk IV.4). 
Een aangepast behandelingsschema werd gebruikt om het effect van combinatie therapie te 
vergroten, ervan uitgaande dat het effect van IFN therapie word! versterkt door reductie van 
de virale load voor start van behandeling. IFN werd toegevoegd aan voorbehandeling met 
tenminste 16 we ken lamivudine therapie (hoofdstuk IV.1 ). Combinatie therapie werd 
gedurende ten minste acht weken gecontinueerd waarna lamivudine werd gestopt en IFN 
monotherapie nog ten minste acht weken werd gegeven. Tijdens lamivudine monotherapie 
daalde HBV DNA met een mediaan van 3.2 log, 66% van deze reductie in virale load werd in 
de eerste vier weken bereikt. Daarna vlakte de daling at (0.2-0.3 log per maand). Het 
toevoegen van IFN zorgde voor een verdere virus onderdrukking met een mediaan van 1.4 
log, hiervan werd 86% bereikt in de eerste vier weken van combinatie therapie. Echter het 
achtereenvolgens stoppen van lamivudine en vervolgens IFN ging gepaard met een 
terugkeer van de virale load in vrijwel aile patienten. HBeAg seroconversie werd bereikt in 
vier van de 24 patienten, het was echter slecht in 2/24 (8%) blijvend. Alhoewel de mate van 
virus suppressie gedurende combinatie therapie met lamivudine en IFN superieur was, werd 
geen voordeel bereikt met het gebruikte behandelingsschema. 
In de tweede studie is het effect van combinatietherapie geevalueerd met behulp van een 
biphasisch mathematisch model (hoofdstuk IV.2). Er werd aangetoond dat combinatie van 
beide middelen de daling van het virus gedurende beide lases versterkt. Het gelijktijdig 
geven van IFN en lamivudine verminderde de halfwaardetijd van het virus en de 
ge"infecteerde eel aanzienlijk. Onafhankelijk van de therapie die werd gegeven werd er een 
correlatie gevonden tussen ALT voor start van behandeling en de mate van daling van HBV 
DNA. Belangrijker, extrapolatie van de gegevens van de tweede lase van het biphasische 
model toonde aan dat, theoretisch, combinatie van beide middelen de geschatte 
behandelingsduur, nodig om klaring van HBV DNA te verkrijgen, verkort en dat het 
percentage patienten wat dit punt bereikt verhoogd word! naar vrijwel 100%. Hoewel 
kortdurende combinatie therapie (16 weken) de effectiviteit in voorafgaande studies niet 
vergrootte, suggereren deze resultaten een sterk voordeel van combinatie therapie boven 
monotherapie met een van beide geneesmiddelen indien dit gedurende een langere periode 
word! gecontinueerd. 
Er is discussie over de duurzaamheid van lamivudine ge"induceerde HBeAg seroconversie. 
Een grate internationale meta-analyse werd opgezet die de individuele patienten data over 
HBeAg seroconversie na IFN, lamivudine of lamivudine-IFN combinatie therapie 
bestudeerde (hoofdstuk IV.3). In 54% van de lamivudine responders werd na 3 jaar follow-up 
een terugkeer van HBeAg in serum geobserveerd, vergeleken met 32% na IFN therapie en 
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23% na combinatie therapie. Een hoge ALT en laag HBV DNA waren positief gerelateerd 
aan een lagere kans op terugkeer, onafhankelijk van de therapie die gegeven werd. Na 
correctie voor baseline factoren, HBV DNA, ALT, ras en geslacht werd een toename van de 
kans op terugkeer gezien na stoppen van lamivudine therapie, echter het risico daalde na 
stoppen van IFN-bevattende therapieen. He! relatieve risico op terugkeer na stoppen van 
lamivudine was 4.6 vergeleken met IFN monotherapie. Deze resultaten tonen dus duidelijk 
aan dat HBeAg-seroconversie na lamivudine minder duurzaam is vergeleken met 
seroconversie na IFN-bevattende therapie. 
Langdurige behandeling met een combinatie van lamivudine en IFN zal waarschijnlijk de 
initiele kans op response vergroten, de duur van de behandeling verkorten en het risico op 
terugkeer van het virus na stoppen van de behandeling verkleinen, in vergelijking met 
monotherapie met een van beide middelen, met name als deze behandeling word! gericht op 
patienten met verhoogde serum transaminasen voor start van therapie. Het effect van 
langdurige combinatie therapie in verschillende patienten populaties en het optimale 
behandelingsschema, dosis en duur van behandeling zijn onderwerp van vervolgstudies. 
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De auteur van dit proefschrift werd op 29 mei 1971 in Eindhoven geboren. Na het V.W.O.-B 
eindexamen aan het Mgr. Zwijsen college te Veghel werd in 1989 gestart met de studie 
geneeskunde aan de Rijksuniversiteit Limburg. Tijdens haar co-schappen werkte zij vanaf 
1995 tot 1997 mee aan een onderzoek naar osteoporose bij patienten met de ziekte van 
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Maastricht (Prof. Dr. R.W. Stockbrugger). Na het behalen van het artsexamen in 1997 was 
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chronische hepatitis B patienten uiteindelijk leidend tot de totstandkoming van dit proefschrift. 
Met de opleiding tot internist werd in januari 2001 begonnen in het Sint Joseph Ziekenhuis in 
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Abbreviations 
AL(A)T 
anti-HBe 
anti-HBs 
AS(A)T 
CCC-DNA 
CHB 
Cl 
CMV 
DNA 
EBV 
EIA 
ELISA 
geq 
HAl 
HAV 
HBcAg 
HBeAg 
HBig 
HBsAg 
HBV 
HCC 
HCV 
HDV 
HIV 
IFN (-a), (-y) 
IL (-2), (-10), (-12) 
IU 
LAM 
LPR 
LSI 
LTx 
MAb 
MU 
PBMC 
PCR 
PCRQ 
RCT 
PEl 
pg 
RNA 
RR 
SD 
SE(M) 
Th 
TN F-a: 
ULN 
alanine aminotransferase 
antibody against HBeAg 
antibody against HBsAg 
aspartate aminotransferase 
covalently closed circular DNA 
chronic hepatitis B 
confidence interval 
cytomegalo virus 
deoxyribonucleic acid 
Ebstein Barr virus 
enzyme immune assay 
enzyme labeled immune solid phase assay 
genome equivalents 
histology activity index 
hepatitis A virus 
hepatitis B core antigen 
hepatitis B envelop antigen 
hepatitis B immune globulin 
hepatitis B surface antigen 
hepatitis 8 virus 
hepatocellular carcinoma 
hepatitis C virus 
hepatitis D virus 
human immunodeficiency virus 
interferon (-alpha), (-gamma) 
interleukin (-2), (-10), (-12) 
international units 
lamivudine 
lympho-proliferative response 
lymphocyte stimulation index 
liver transplantation 
monoclonal antibody 
mega units 
peripheral blood mononuclear cell 
polymerase chain reaction 
quantitative polymerase chain reaction 
randomised controlled trial 
Paul Ehrlich Institute 
pico gram 
ribonucleic acid 
relative risk 
standard deviation 
standard error (of the mean) 
T helper cell 
tumor necrosis factor alpha 
upper limit of normal 
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